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CHAPTER 1:
General introduction
Heart failure (HF) can be defined as a syndrome in which patients
generally display shortness of breath and fatigue, show signs of fluid retention,
and have objective abnormalities in the structure and/or functionality of the
heart (1). Additional terms to characterize heart failure patients include acute
vs. chronic, and diastolic vs. systolic. Acute refers to a recent onset and
transient state of HF, whereas chronic refers to a persistent condition of HF in
which the patient is in a stable, worsening, or decompensated state. Patients
with diastolic HF have symptoms of HF with a preserved left ventricular
ejection fraction. Systolic refers to an impaired left ventricular pump function
(left ventricular ejection fraction - LVEF) of the heart. A typical, but arbitrary
cut-off for LVEF is 40 percent (1). This thesis focuses on chronic systolic heart
failure (CHF).
The symptoms and signs of HF are the key to early detection because
that is what causes patients to seek medical attention. Fatigue is a very
important sign of HF, and is often rated as the most disabling symptom in HF
(2). Nevertheless, fatigue in HF is poorly understood, is underreported in the
cardiovascular literature, and is seldom a target for intervention (3-6). Hence,
more research in this area is needed.
Standard HF treatment involves the prescription of a diuretic (to control
fluid retention), an angiotensin-converting enzyme (ACE) inhibitor (to lower
blood pressure), a beta-blocker (to slow down heart rate and lower blood
pressure), a angiotensin II receptor antagonists (to control blood pressure),
and aldosterone antagonist (for its diuretic effects). Sometimes digoxin is
added to improve the pump efficiency of the heart. Some heart failure patients
may require surgery, such as coronary artery bypass graft (CABG) surgery or
heart valve repair, to improve damage to the heart or implantable devices to
control irregular heart rhythms or to resynchronize the heart. As a last resort,
patients with severe heart failure who do not respond to standard treatment
may be eligible for a heart transplant (1,7).
The prevalence of HF increases with age. Epidemiological studies have
shown that the population prevalence of HF is between 2 and 3 percent with a
large increase after 75 of age up to 10-20 percent (8,9). The prevalence of HF
has increased over the last decades as a result of the ageing of the population,
and improved treatment and secondary prevention of coronary artery disease,
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which is the most common cause of HF. Despite improved treatment
modalities, HF mortality rates remain high, with 50 percent dying within 4
years (1,10).
Predicting HF prognosis remains challenging due to variations in
etiology, treatment, and individual progression. Traditional risk factors (e.g.
higher age, hypertension, low LVEF) are only able to predict a moderate
proportion of the variance in mortality (11). Hence, exploring relatively
understudied determinants is warranted with psychosocial factors being an
interesting venue for study (12). In addition, patient-centered outcomes have
gained importance because, from a patient's perspective, health status is
generally as important as prolonged survival (13-18).
Psychosocial factors in CHF
So far, studies have primarily focused on the role of depression in CHF
(19-23). Depression has been associated with an increased risk of mortality
and poor health status, and this adverse effect has been found to be consistent
across studies (23). Other psychosocial factors that have been studied in the
context of CHF are anxiety, social support, and Type D personality. Mixed
results have been reported for anxiety as a predictor of mortality (19,21,24),
whereas stronger evidence was found for low social support as a predictor for
poor CHF outcome (25,26).
Recently, the role of Type D personality, a joint tendency towards
negative affectivity and social inhibition (27), has been studied in CHF (15-
17,28-32). Schiffer et al. found that Type D personality was an independent
predictor of respectively anxiety (30), depressive symptoms (17), health status
(16), and cardiac mortality in CHF (31).
Vital exhaustion
A psychological factor that has been overlooked in the context of CHF
thus far is vital exhaustion (VE). Vital exhaustion has three defining
characteristics: feelings of excessive fatigue and lack of energy, increasing
irritability, and feelings of demoralization (33,34). The concept of vital
exhaustion was constructed as a result of the notion that patients with a
myocardial infarction (MI) often report feelings of unusual tiredness and
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malaise in the period prior to the MI (35). Several studies have shown that
vital exhaustion predict coronary events in initially healthy persons (34,36), as
well as in patients with established coronary artery disease (37,38).
Several potential (physiological) mechanisms have been studied to
explain the relationship between vital exhaustion and adverse coronary events.
The results of these studies suggest that exhausted subjects are characterized
by: lower values of morning cortisol (39), lower levels of adrenocorticotropic
hormone (40,41), increased blood coagulability together with a decreased
fibrinolysis (42,43), higher levels of the cytokines IL-10, IL-6, and TNF-a (44),
higher levels of C-reactive protein (45), an increased number of leukocytes
(45), higher antibody titers for cytomegalovirus (44), higher antibody titers for
chlamydia pneumoniae (44), a higher viral load (46), a reduced amount of
deep sleep (47), decreased heart rate variability (48), and lower concentration
of macrophage migration inhibitory factor (49). It is concluded that vital
exhaustion is associated with decreased activity of some important recovery
mechanisms in combination with heightened inflammation (35).
The gold standard to determine whether a variable holds a causal
relationship with an outcome variable is to conduct a randomized clinical trial.
Therefore, the Exhaustion Intervention Trial (EXIT) was designed to evaluate
the impact of a behavioral intervention on vital exhaustion and subsequent
prognosis. Although the intervention had a beneficial effect on feelings of
exhaustion, it could not be demonstrated that the intervention reduced the risk
of a new coronary event within 2 years (50). Hence, there is currently no
evidence that vital exhaustion qualifies as a modifiable risk factor in patients
with coronary artery disease. Similar conclusions were drawn in related trials
that focused on depression (51-53).
Vital exhaustion has sometimes been criticized for its overlap with
depression and for its definition (54-56). It has even been argued that
depression and vital exhaustion are interchangeable (55), although empirical
support for that point of view is limited (54,56,57). The Maastricht
Questionnaire (MQ), the primary tool to assess vital exhaustion, was originally
designed to assess feelings of excessive fatigue, increasing irritability, and
demoralization. However, this measure has also been shown to be closely
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related to symptoms of fatigue, symptoms of depression, sleep problems, and
lack of concentration (54).
Within the framework of CHF, little research has been performed on the
role and nature of vital exhaustion. Still, specifically in CHF patients, studying
its association with fatigue, one of the core symptoms of CHF, may lead to new
insights with respect to disease progression (1,7).
Symptoms of fatigue in CHF
Characteristic symptoms of CHF are breathlessness, tiredness, and
fatigue (1). Although it is widely acknowledged that fatigue is an important
symptom of CHF, from a research perspective it has received little attention.
Recent studies have underlined the importance of symptoms both in terms of
prognosis (58,59) and health status (60), with fatigue often rated as one of the
most disabling symptoms in chronic heart failure (2). In addition, it was shown
that self-assessed symptoms and New York Heart Association (NYHA)
classification were not coherent (61), indicating that there was little agreement
between the patient and physician rated CHF symptoms. Self-assessed fatigue
may therefore provide useful additional information about the patients' clinical
and prognostic status.
Fatigue in CHF is not yet fully understood. Haemodynamically,
symptoms of fatigue during exercise are thought to arise from failure of muscle
perfusion due to an inadequate rise in cardiac output. However, many studies
have shown that there is no relation between cardiac performance and exercise
performance (4,5). Recently, it has been suggested that chronic, low grade
haemodynamic stress as seen in CHF, may lead to dominance of catabolic
processes. This in turn leads to skeletal myopathy, causing the sensation of
fatigue (62). So fa r, there is limited empirical evidence to fully support this
hypothesis.
Predicting fatigue in CHF has proven to be difficult and few studies have
focused on this. Only one small study in 75 women with HF specifically
addressed this issue and found that symptoms of dyspnoea were associated
with fatigue (3). Hence, more studies are needed to get better insight into its
predictors. The dynamic nature of fatigue warrants the investigation of these
symptoms prospectively over time. Efforts should be made to obtain knowledge
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about subgroups of CHF patients that are at increased risk to develop worse
fatigue status over time, thereby providing an opportunity for risk stratification
and prevention. Moreover, the prognostic impact of changes in self-reported
fatigue should be examined as well.
An important issue of studying psychological factors in heart disease is
to examine the degree of distinctiveness between overlapping constructs to
avoid redundancy and to promote efficient determination of patients with high-
risk profiles (63). The experience of fatigue might depend on several coexisting
conditions and factors that could be of relevance for disease progression (61).
For instance, depression is common in heart failure patients and has been
associated with poor outcome (23). Therefore, investigating the
interrelationship between fatigue and depression in the context of CHF is
needed.
Aim of the present thesis
This thesis presents the results of several studies. Most findings are
based on an ongoing longitudinal study examining the role of psychological
factors in CHF. Patients were recruited from the TweeSteden Hospital in Tilburg
and Waalwijk, the Netherlands. Psychological, demographic, and clinical
variables were collected at baseline, 2-, 6-, 12-, and 18-months follow-up. The
research protocol was approved by the local medical ethics committee, and the
study was conducted in accordance with the Helsinki Declaration. Written
informed consent was obtained from every patient. The chapters described in
this thesis are based on data from this study, except for chapter 3,4, and 6.
These chapters also use data from other studies. Chapter 3 is partly based on
419 consecutive percutaneous coronary intervention (PCI) patients recruited in
a study at the Erasmus Medical Center Rotterdam, the Netherlands (64).
Chapter 4 is partly based on 407 patients that were recruited as part of the
DepreMI study (65), which is a naturalistic follow-up study on the impact of
depressive symptoms on cardiac prognosis in MI patients in four hospitals in
the North of the Netherlands. Finally, chapter 6 is partly based on 80
consecutive stroke patients recruited at nursing home "De Hazelaar", Tilburg,
the Netherlands, and 160 healthy controls from the general Dutch population.
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As mentioned before, both vital exhaustion and fatigue have received
little attention in the context of CHF. Therefore, the overall aim of this thesis
was to examine the nature, course, and prognostic impact of vital exhaustion
and fatigue in CHF patients. Figure 1 shows a schematic presentation of the
outline of the thesis.
Figure 1. Outline of thesis
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Outline of the thesis
Part A: Vital exhaustion
The first part of this thesis focuses on vital exhaustion. In a prospective
study, principal component analysis was used to determine the structure of
vital exhaustion in patients with CHF. The derived components were used to
identify subgroups with different symptom profiles applying latent class cluster
analysis. Subsequently, the impact of the symptom profiles on health status
and cardiac rehospitalization at 6-month follow-up was investigated (chapter
2).
In chapter 3, the effect of ischemic heart disease stage on symptoms
of fatigue and depression, i.e. the primary components of vital exhaustion, was
examined using a prospective design, using two different samples to represent
ischemic heart disease stage: PCI patients representing early ischemic heart
disease stage, and CHF patients representing end-stage ischemic heart
disease. In addition, the impact of Type D personality on fatigue and
depression was evaluated.
A third study on vital exhaustion includes a sample of MI and CHF
patients to investigate the course and characteristics of vital exhaustion over a
12-month period. The different trajectories of vital exhaustion extracted using
latent class growth modeling were used to examine their effect on
cardiovascular prognosis (chapter 4).
Part B: Symptoms of fatigue
The second part of this thesis focuses on symptoms of fatigue. In line
with previous research (66), two different measures of fatigue are used
throughout these chapters: 1) The Dutch Exertion Fatigue Scale which
measures fatigue directly related to performing of activities in daily living, and
the Fatigue Assessment Scale which measures an overwhelming, sustained
sense of fatigue that does not necessarily have a relationship with exertion.
Predictors of fatigue in CHF are largely unknown. Therefore, the aim of
chapter 5 was to examine clinical and psychological predictors of fatigue in
CHF using a prospective design.
In chapter 6, the psychometric properties of the Fatigue Assessment
Scale were tested in a sample of stroke patients. Levels of fatigue in stroke
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have so far only been compared to healthy controls and patients with multiple
Sclerosis. Since stroke is a vascular disease, it is interesting to compare levels
of fatigue to cardiac patients as well. Therefore, levels of general fatigue were
compared as reported by stroke patients, CHF patients, and healthy controls.
Levels of fatigue are not necessarily stable over time. The dynamic
nature of fatigue warrants the investigation of these symptoms prospectively.
The aims of the study presented in chapter 7 were to determine clinical,
demographic, and psychological predictors of changes in fatigue over a 12-
month period and to examine whether these changes in fatigue are predictive
of adverse cardiac events occurring beyond 12 months.
In chapter 8, a similar approach is adopted as in chapter 4 to study
the course of exertion and general fatigue over a 12-month period. Different
trajectories of fatigue were derived using latent growth mixture modeling.
Next, these different trajectories were linked to mortality beyond 12 months.
The last study presented in this thesis adds to a recent study of Schiffer
et al. (67) which showed that somatic/affective rather than cognitive/affective
symptoms of depression predict mortality in CHF. Since fatigue is highly
prevalent among CHF patients and fatigue is a core characteristic of the
somatic/affective domain of depression, the aim of chapter 9 was to examine
whether fatigue may explain away the relationship between somatic/affective
symptoms of depression and mortality in CHF patients.
Finally, main outcomes, strengths and weaknesses of the studies are
discussed in chapter 10. Recommendations for future research as well as for
clinical practice are provided.
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ABSTRACT
Objective: The aim of this study was to examine the components of vital
exhaustion (VE) in chronic heart failure (CHF) patients, and to examine
whether psychological symptom profiles based on these components are
differently associated with health status and cardiac rehospitalization.
Methods: Consecutive CHF patients (N=381) were assessed for VE at baseline
using the Maastricht Questionnaire (MQ) and for health status by means of the
Minnesota Living With Heart Failure Questionnaire (MLWHFQ) at 6-month
follow-up. Information on cardiac rehospitalization was obtained from the
patients medical record. Results: Principal component analysis revealed 4
essential features of VE: Fatigue, cognitive-affective depressive symptoms,
sleep difficulties, and lack of concentration. Latent class cluster analysis using
these components identified 3 subgroups with different symptom profiles: A
subgroup without VE, a first vitally exhausted subgroup (VEl; fatigue, lack of
concentration, but with relative absence of cognitive-affective depressive
symptoms and sleep difficulties), and a second, more severe, vitally exhausted
subgroup (VE2; elevated levels on all components). Both vitally exhausted
subgroups were more likely to have impaired health status (VEl : B=.36,
p<.001; VEZ: B=.71, p<.001). VEZ was also associated with increased risk for
cardiac rehospitalization at 6-month follow-up (OR=2.98; 95%CI 1.01-8.83,
p=.049). Conclusions: VE in CHF comprised 4 components (fatigue, cognitive-
affective depressive symptoms, sleep difficulties, and lack of concentration)
from which 3 different symptom profiles were derived. Subgroups with
symptoms of vital exhaustion were associated with adverse clinical outcome in
CHF. In clinical practice, these results may help identify distinct groups of
patients with potentially differential risks of adverse health outcomes.
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INTRODUCTION
Fatigue and vital exhaustion (VE) are frequently reported symptoms in
patients with coronary artery disease and chronic heart failure (CHF) (1-3). The
most commonly used definition of VE is that of unusual tiredness, increased
irritability, and feelings of demoralization (4). VE has been associated with a 2
to 3 fold increased risk of mortality and morbidity in patients with coronary
artery disease (2,5), and several potential biological pathways have been
identified to explain this association. Vital exhaustion has been shown to relate
to increased lipid metabolism (6), hypocortisolemia (7,8), reduced fibrinolytic
capacity (9,10), parasympathetic withdrawal (11), and increased levels of
cytokines, e.g. IL-6 (12,13).
The 21-item Maastricht Questionnaire (MQ) is often used to assess VE
(4). Previous studies have shown that VE as measured by the MQ is not a
unidimensional construct, but comprises different factors such as symptoms of
fatigue, depressive symptoms, sleep problems, and lack of concentration (14-
16) Nonetheless, in most studies, the total score was computed and
subsequently dichotomized using a standardized cut-off of 14 in order to
classify patients as either vitally exhausted or not vitally exhausted (17).
As a consequence, it is not fully understood what components of VE
account for the association with clinical outcome in cardiac patients. One study
in healthy men reported that, in a multivariate model, it was the fatigue
subscale, and not the depression or irritability subscale, that predicted incident
myocardial infarction (18). A few other studies examined the overlap between
VE and depressive symptoms. In a large-scale study of Kopp et al. (19), VE
and depressive symptoms were differently related to relevant external criteria
suggesting that the constructs are distinct from each other. Furthermore, VE
and depression shared less than 40 percent of the variance. The latter result
was confirmed by Kudielka et al. (14), and McGowan et al. (15). However, a
study by Wojciechowski et al. (20) found no support for the hypothesized
separate conceptual identity of depression and vital exhaustion.
Next to studying components, it is also important to examine symptom
profiles. Kubzansky et al. (21) recently stated that identification of risk profiles
across the spectrum of symptoms and syndromes characterizing psychological
discomfort, including subsyndromal conditions, might increase the sensitivity of
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epidemiological prediction models and clarify the pathophysiological pathways
linking negative psychological states to cardiac disease. In the context of VE, it
would therefore be interesting to determine whether psychological symptom
profiles based on the underlying components of VE are differentially related to
clinical outcomes in CHF patients.
The objectives of the present prospective study were 1) to examine the
components of vital exhaustion in CHF patients, and 2) to examine whether
psychological symptom profiles based on these components are differently
associated with health status and cardiac rehospitalization.
METHODS
Patients and design
The sample included 381 CHF patients, with systolic heart failure and a
left ventricular ejection fraction (LVEF) 540%, visiting the heart failure
outpatient clinic of the Twee Steden Hospital, Tilburg, the Netherlands. Patients
with diastolic heart failure, age 280 years, myocardial infarction in the month
prior to inclusion, other life-threatening diseases, and no or insufficient
understanding of spoken and written Dutch language were excluded.
The design of the study was prospective, with patients completing a
questionnaire assessing VE at baseline and health status at 6-month follow-up.
The study protocol was approved by the local medical ethics committee in
Tilburg, the Netherlands. The study was conducted conform to the Helsinki
Declaration and every patient provided written informed consent.
Demographic and clinical variables
Demographic variables included sex, age, education, and marital
status. Clinical variables comprised LVEF, NYHA class, etiology of CHF, co-
morbidity (hypertension, diabetes, stroke, COPD, renal disease, liver disease),
cardiac history (MI, PCI, CABG), cardiac medication, and body mass index
(BMI). Information on clinical variables was obtained from the medical records
and from the treating cardiologist.
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Vital Exhaustion
VE was assessed by the 21-item Maastricht Questionnaire (4). Each
item is rated according to a three-point scale (Yes=0; 7=1; No=2), with a scale
score obtained by summing the answers. The reliability of the total scale is
good with Cronbach's alpha of 0.89 (5).
Endpoints at 6-month follow-up
Endpoints in this study were health status and cardiac rehospitalization
at 6-month follow-up. The Minnesota Living with Heart Failure Questionnaire
(MLWHFQ), a disease-specific instrument, was used to assess patient-rated
health status at baseline (for control purposes) and follow-up (22). This
questionnaire consists of 21 items that are answered on a four-point Likert
scale. The reliability of the scale is good with Cronbach's alpha of 0.95 (22). A
higher score on the MLWHFQ represents a poorer health status. The MLWHFQ
is a frequently used measure to assess health status in CHF patients (23).
Patients' hospital medical records were used to assess whether patients had
been readmitted for cardiovascular causes between baseline and 6-month
follow-up.
Statistical analyses
Principal component analysis (PCA) with oblimin rotation was used to
determine the underlying structure of the MQ. Kaiser's criterion was adopted to
identify the number of components, and subsequent KMO (Kaiser-Meyer-Olkin-
Criteria) and Bartlett's test of sphericity were applied as fit indices. The
resulting components were used to construct homogeneous subscales of VE.
For each subscale, those items with the component loadings >.40 and cross
loading differences >.20 were selected. Subscale homogeneity was examined
by cronbach's alpha.
Identification of groups was obtained through latent class (LC) cluster
analysis. LC cluster analysis is a state-of-art model-based clustering approach
that has some important advantages over standard cluster analysis techniques.
In LC cluster analysis, the cluster criterion is less arbitrary, no decisions have
to be made about the scaling of the observed variables, and there are more
formal criteria to make decisions about the number of clusters (24). In the
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present study, we assumed that all the within-cluster covariances were zero
(local independence), and the Bayesian Information Criterion (BIC) was used to
determine the optimal number of clusters.
For comparison between groups we used the chi-square test for
discrete variables. Adjusted standardized residuals were used to identify groups
responsible for significant differences. A residual greater than 2.0 was taken to
indicate a significantly higher frequency, and a residual less than -2.0 was
considered to indicate a significantly lower frequency (25). In case of
continuous variables, analysis of variance (ANOVA) was adopted. Multivariate
ANOVA was employed to examine differences on subscale measures between
groups identified by cluster analysis. The Student-Neuman-Keuls test was used
for post-hoc analysis. Multiple regression analysis was used to assess the
relationship between group membership and health status at 6-month follow-
up, whereas logistic regression was used to assess the impact of group
membership on rehospitalization at 6-month follow-up. The assumptions for
multiple linear regression and logistic regression were checked and met. The LC
cluster analysis was performed with the LCA program Latent GOLD (26). All
other data were analyzed using SPSS 14.0.2 for Windows.
RESULTS
Components of vital exhaustion
PCA revealed a 4-component solution in the underlying structure of the
MQ (Table 1). KMO (0.91) and Bartlett's test of sphericity (X: (210) = 2765,
p<.001) indicated that PCA was adequate for these data. Items 6, 9, and 12
were excluded from further analyses. The subscales that were constructed from
the PCA reflected, respectively, 'fatigue' (a=.84), 'cognitive-affective
depressive symptoms' (a=.83), 'sleep difficulties' (a=.67), and 'lack of
concentration' (a=.61). The labeling of the components was based on previous
literature (15), and face validity.
All components were associated with impaired health status at 6-month
follow-up (.29 <r< .59; p<.001). After controlling for the interrelatedness of
these components, fatigue (B=.44; p<.001), cognitive-affective depressive
symptoms (B=.19; p<.01), and sleep difficulties (B=.10; p<.05) remained
significantly associated with impaired health status at 6-month follow-up.
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Table 1. Components of vital exhaustion
Itern Loading Content
Component  1:  Fatigue
5 .74 Do you have the feeling that you have not been
accomplishing much lately?
8 .71 Do you lately feel more listless than before?
1 .71 Do you often feel tired?
14 .66 I feel fine (reverse).
15 .65 Do you feel that your body is like a battery that is losing
its power?
17 .53 Do you have the feeling these days that you just do not
have what it takes anymore?
4 .50 Do you feel weak all over?
9+ .28 I enjoy sex just as much as I used to (reverse).
Component  2:  Cognitive-affective  depressive  symptoms
13 .83 Do you feel you want to give up trying?
16 .81 Would you want to be dead at times?
18 .70 Do you feel dejected?
7 .64 Do you believe that you have come to a dead end?
19 .60 Do you feel like crying sometimes?
10 .55 Have you experienced a feeling of hopelessness recently?
62 .45 Do you have the feeling that you cannot cope with
everyday problems as well as you used to?
Component 3: Sleep difficulties
2 .82 Do you often have trouble falling asleep?
3 .78 Do you wake up repeatedly in the night?
20 .57 Do you ever wake up with a feeling of exhaustion and
fatigue?
Component 4:  Lack of concentration
11 .82 Does it take you more time to grasp a difficult problem
than it did a year ago?
21 .78 Do you have increasing difficulty in concentrating on a
single subject for long?
12t .39 Do little things irritate you more than they used to?
t Items with component loadings <.40 or cross loading differences <.20 were excluded from further
analyses.
Furthermore, fatigue (OR=1.04; 95%CI 1.00-1.08, p<.05) and cognitive-
affective depressive symptoms (OR=1.03; 95%CI 1.00-1.06, p<.05) were
associated with cardiac rehospitalization at 6-month follow-up in bivariate
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analysis. However, after controlling for their interrelatedness, both components
became non-significant.
Profiles of vital exhaustion
As shown in Table 2, a solution with three patient clusters resulted in
the lowest BIC-value. Figure 1 visualizes the three VE profiles. Cluster 1
(24.1%; n=92) is characterized by a relative absence of VE, and is therefore
labeled the 'No VE group'. Cluster 2 and 3 can both be labeled as groups with
manifest symptoms of VE. Cluster 2 (47.2%; n=180) is characterized by
increased levels of fatigue and decreased concentration, but also by a relative
absence of cognitive-affective depressive symptoms and sleep difficulties.
Although the differences between cluster 1 and 2 with respect to cognitive-
affective depressive symptoms and sleep difficulties were statistically
significant, the small to moderate effect sizes may indicate lack of clinical
significance, supporting our characterization of cluster 2. Finally, cluster 3
(28.6%; n=109) is characterized by the presence of manifest symptoms of VE,
including cognitive-affective symptoms of depression and sleep difficulties.
Table 2. Model clusters and diagnostic indices
Model LLt BIC (LL) ABIC (LL) * Parameters              Df
1 cluster -2868 5950         -            36          345
2 cluster -2727 5698 -252 41 340
3 cluster -2702 5678 -20 46 335
4 cluster -2698 5698 20           51          330
5 cluster -2692 5717         19           56          325
6 cluster -2688 5738         21           61          320
t LL = log likelihood
* ABIC (LL) = BIC {more complex model} - BIC {simpler model}, a negative value
indicates that improved model fit outweighs increased model complexity
Cluster characteristics are shown in Table 3. Based on the adjusted
standardized residuals, patients in cluster 1 were more likely to be male and to
have no academic education, and less likely to have NYHA-class III/IV heart
failure, comorbidities, diabetes, or diuretics treatment. Patients in cluster 3
were younger, and had a higher BMI compared with cluster 1 and 2.
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Table 3. Demographic and medical characteristics stratified by cluster membership
Total sample Cluster 1* Cluster 2* Cluster 3* p-value
(n=92) (n=180) (n=109)
Age, mean (SD) 65.7 (10.4) 66.6 (9.7) 66.7 (10.6) 63.5 (10.4) .03
Male sex, % (n) 72.2 (275) 81.5 (75) 73.3 (132) 62.4 (68) .009
Having a partner, % (n) 72.2 (275) 79.3 (73) 74.4 (134) 62.4 (68) .02No academic education, % (n) 85.8 (327) 78.3 (72) 87.2 (157) 89.9 (98) .05NYHA-class III/IV, % (n) 39.6 (151) 27.2 (25) 39.4 (71) 50.5 (55) .003
LVEF: Mean (SD), mean (SD) 30.8 (6.9) 31.2 (7.5) 30.4 (6.8) 31.0 (6.4) .65Ischemic etiology, % (n) 54.1 (206) 51.1 (47) 53.9 (97) 56.9 (62) .71
Cardiac historyt, % (n) 57.5 (219) 55.4 (51) 56.7 (102) 60.6 (66) .73
Smokers, % (n) 23.9 (91) 28.3 (26) 22.8 (41) 22.0 (24) .52
Comorbidity*, % (n) 58.3 (222) 46.7 (43) 62.8 (113) 60.6 (66) .03
Diabetes, % (n) 24.9 (95) 16.3 (15) 25.6 (46) 31.2 (34) .05
ACE-inhibitor, % (n) 71.4 (272) 70.7 (65) 72.2 (130) 70.6 (77) .94
Diuretics, % (n) 72.7 (277) 59.8 (55) 73.3 (132) 82.6 (90) .001
Digoxin, % (n) 24.7 (94) 23.9 (22) 27.8 (50) 20.2 (22) .34
Beta blocker, % (n) 66.9 (255) 75.0 (69) 65.9 (118) 62.4 (68) .17
Statins, % (n) 50.9 (194) 51.1 (47) 51.1 (92) 50.5 (55) .99
Aspirin, % (n) 40.9 (156) 37.0 (34) 43.3 (78) 40.4 (44) .59
BMI, mean (SD) 28.1 (5.3) 27.0 (4.9) 27.8 (4.4) 29.4 (6.6) .005
* Cluster 1=no vital exhaustion; Cluster 2=vital exhaustion with relative absence of depressive symptoms and
sleep difficulties; Cluster 3=vital exhaustion with depressive symptoms and sleep difficulties
t History of MI, CABG, PCI
* Stroke, COPD, hypertension, peripheral arterial disease, renal insufficiency
Figure 1. Symptom profiles of vital exhaustioni
El   Cluster 1: No vital exhaustion.
    Cluster 2: Manifest vital exhaustion with a relative
absence of cognitive-affective depressive symptoms
and sleep difficulties.
       Cluster
3: Manifest vital exhaustion with cognitive-
affective depressive symptoms and sleep difficulties.
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In addition, cluster 3 contains relatively more females, more patients without a
partner, more patients in NYHA-class III/IV, and more patients on diuretics
than would be expected from the independence hypothesis.
Multivariate ANOVA revealed that there was an overall significant main
effect for cluster membership on the components of VE (Wilks lambda=0.15; F
(8,732)=145.1, p<.0001) adjusting for age, sex, marital status, educational
level, NYHA-class, comorbidities, diabetes, diuretics and BMI. Only main effects
and two-way interactions were included in the model. This finding indicates
that differences between clusters on VE cannot be explained by the included
covariates. Therefore, the clusters provide unique information on the
identification of subgroups of vital exhaustion in patients with CHF.
Vital exhaustion profiles and health status
The mean level of impaired health status was the highest among
patients in cluster 3 (M=44.5, SD=21.5); patients in cluster 2 (M=26.7,
SD=15.9) also reported higher levels of impaired health status as compared to
cluster 1 patients (M=11.6, SD=12.5; all p<.001). In multivariate analyses
using cluster 1 as the reference category, health status was associated with
exhaustion subtype after controlling for age, sex, marital status, educational
level, NYHA-class, comorbidities, diabetes, diuretics and BMI. The VE group
with cognitive-affective depressive symptoms and sleep difficulties (Cluster 3;
B=.71, p<.001) and the VE group with a relative absence of cognitive-affective
depressive symptoms and sleep difficulties (Cluster 2; B=.36, p<.001) were
associated with impaired health status as compared to the no vital exhaustion
subgroup. In addition, higher age (B=.12, p<.05) and NYHA-class (B=.12;
p<.05) were also associated with impaired health status. Other variables were
not associated with health status in multivariate analysis. After controlling for
health status at baseline, exhaustion subtype (Cluster 3; B=.27, p<.001;
Cluster 2; B=.14, p<.01) remained a significant predictor of impaired health
status at 6-month follow-up.
Vital exhaustion profiles and cardiac rehospitalization
Over the period of follow-up, 39 patients (10.2%) were readmitted for
cardiovascular causes. As displayed in Figure 2, vitally exhausted patients with
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all symptoms, including cognitive-affective depressive symptoms and sleep
difficulties (cluster 3) were more likely to be rehospitalized as compared to
patients without VE (cluster 1). Vitally exhausted patients with a relative
absence of cognitive-affective depressive symptoms and sleep difficulties
(cluster 2) also showed a tendency to more hospitalizations as compared to
patients in cluster 1, but this was not statistically significant. In multivariate
logistic regression including the same covariates as in the previous section,
cluster 3 was a significant predictor of cardiac rehospitalization at 6 month
follow-up (OR=2.98; 95%CI 1.01-8.83, p=.049), whereas cluster 2 did not
reach statistical significance (OR=1.77; 95%CI 0.62-5.03, P=.29).
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DISCUSSION
The aim of the study presented here was to examine components of VE
in CHF patients and the associations of symptom clusters with health status
and cardiac rehospitalization at 6-month follow-up. Results showed that the
underlying structure of VE consisted of four components: fatigue, cognitive-
affective depressive symptoms, lack of concentration, and sleep difficulties. The
labeling of the components was based on previous literature (15), and face
validity. Fatigue, cognitive-affective depressive symptoms, and sleep difficulties
were independently associated with impaired health status at 6-month follow-
up. In addition, fatigue and depressive symptoms were associated with cardiac
rehospitalization at 6-month follow-up in bivariate analysis.
Latent class cluster analysis based on the components of VE revealed
three symptom clusters: a subgroup without manifest symptoms of VE, and
two subgroups with manifest symptoms of VE characterized by presence of
fatigue and lack of concentration. Importantly, one VE subgroup was
characterized by a relative absence of cognitive-affective depressive symptoms
and sleep difficulties, while the other VE subgroup had elevated levels on all
components. Patients in the two VE subgroups were more likely to report
impaired health status at follow-up as compared to the subgroup without VE.
Furthermore, only the VE subgroup with cognitive-affective depressive
symptoms and sleep difficulties (cluster 3) was an independent predictor of
cardiac rehospitalization at follow-up. Vitally exhausted patients with a relative
absence of cognitive-affective depressive symptoms and sleep difficulties
(cluster 2) did however show a tendency to experience more events as
compared to patients without VE, though this did not reach statistical
significance.
The components of VE obtained in the present study are in line with
previous research (14-16). Fatigue and cognitive-affective depressive
symptoms accounted for the greatest part of explained variance in the MQ and
therefore comprised the two predominant components of VE. We were however
unable to show which of these two components is more important when it
comes to predicting objective clinical outcome (i.e. rehospitalization). In fact,
our findings suggest that it is the shared variance between fatigue and
cognitive-affective depressive symptoms that predicts cardiac rehospitalization.
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Obviously, it is too soon to draw firm conclusions about the exact role of
fatigue and cognitive-affective depressive symptoms and their interrelationship
in predicting cardiac outcome. Some studies suggest that fatigue has the
strongest predictive power (18), whereas others put cognitive-affective
depressive symptoms forward as the strongest predictor (16,27). Large-scale
studies with long-term follow-ups and hard outcomes are necessary to come to
more definite answers.
One of the interesting aspects of the present study was the cluster
analytic approach. Instead of evaluating the predictive qualities of the
individual components, cluster analysis enabled us to identify high-frequent
symptom profiles within a given sample using all derived components. That
means it focuses on clustering of psychological risk factors rather than focusing
on a single risk factor. Such an approach was recently encouraged by Suls and
Bunde (28). In fact, there needs to be more appreciation that the clustering
and overlap of negative affective dispositions may make specificity of emotion
less critical for cardiac risk. For example, fatigue and cognitive-affective
depressive symptoms may both increase the risk of poor health outcomes
because they share a general disposition to experience chronic and intense
negative emotions. Kubzansky and colleagues (21) also argued that identifying
various forms of distress, even in their less severe states, may provide an
important avenue for early intervention. Effective treatment targeting
psychosocial risk factors in CAD patients requires an accurate characterization
of who is at risk for adverse outcomes. A more detailed examination of the
symptom profiles may better inform the development of more effectively timed
and more specifically tailored behavioral interventions.
The results of this study suggest that focusing on symptoms of
depression alone may not be sufficient since patients with elevated levels of
fatigue and lack of concentration, but with a relative absence of depressive
symptoms and sleep difficulties, also had impaired health status at follow-up.
In addition, this cluster showed a tendency to be associated with cardiac
rehospitalization as well. This "subclinical" group can therefore be an
interesting study target. An important next step is to evaluate the effect of this
symptom cluster on cardiac mortality.
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This study has a number of limitations. First, there may have been a
bias in the selection of patients. The cardiologist or heart failure nurses asked
patients to participate in the study, and this interaction pattern might have
influenced selection. Second, the follow-up period was relatively short and we
did not include mortality as an endpoint. Third, we did not screen for major
depression in this study and were therefore not able to control for the effect of
major depression on cardiac prognosis. Our study also has a number of
strengths, including the use of valid and reliable questionnaires, a state-of-the-
art model-based clustering approach, and a prospective design to validate the
derived clusters.
In conclusion, the underlying structure of VE can be characterized by
fatigue, cognitive-affective depressive symptoms, sleep difficulties, and lack of
concentration. Symptom profiles based on these features revealed a subgroup
without VE and two subgroups with VE. Both VE subgroups were associated
with impaired health status, despite the relative absence of cognitive-affective
depressive symptoms and sleep difficulties in one of these subgroups. The
subgroup with cognitive-affective depressive symptoms and sleep difficulties
was at increased risk for cardiac rehospitalization. This study needs to be
replicated in a similar sample with a longer follow-up using mortality as an
endpoint. The profiles of VE based on the underlying structure reported here
provide a basis for profile analysis of psychological symptom change in
outcome studies with cardiac patients and are potentially valuable for both
research and clinical practice.
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CHAPTER 3:
Symptoms of fatigue and depression in ischemic heart disease
are driven by personality characteristics rather than disease
stage: A comparison of CAD and CHF patients
Otto RF Smith, Susanne S Pedersen, Ron T van Domburg, Johan Denollet
European  Journal  of Cardiovascular  Prevention  and  Rehabilitation  2008;15:583-588
ABSTRACT
Background: Symptoms of fatigue and depression are prevalent across stages
of ischemic heart disease (IHD). We examined (1) the effect of both the IHD
stage and Type-D personality on fatigue and depressive symptoms at 12-
month follow-up, and (2) whether the effect of type-D personality on these
symptoms is moderated by IHD stage. Methods: Two different samples of
patients were included to represent IHD stage: 401 PCI patients (early-stage
IHD) and 105 ischemic CHF patients (end-stage IHD) completed the DS14
Type-D Scale at baseline. Logistic regression analysis was used to examine the
impact of IHD stage and type-D personality on fatigue and depression at
follow-up. Results: Disease stage was neither associated with symptoms of
fatigue (p=.99) nor depression (p=.29) at 12 months. In contrast, type-D
personality was shown to predict both symptoms of fatigue (OR=2.96; 95%CI
1.92-4.58, p<.001) and depression (OR=4.91; 95%CI 3.16-7.65, p<.001) at
follow-up; the effect of type-D personality on these symptoms was not
moderated by disease stage. In multivariable analysis, type-D remained a
significant predictor of symptoms of fatigue (OR=3.14; 95%CI 1.98-4.99,
p<.001) and depression (OR=5.90; 95%CI 3.60-9.67, p<.001), also after
controlling for symptom levels at baseline. Conclusion: Type-D personality but




Fatigue is prevalent across stages of ischemic heart disease (IHD).
Symptoms of fatigue have previously been reported by patients with stable and
unstable angina [1], myocardial infarction (MI) [2,3], and chronic heart failure
(CHF) [4,5]. Although the prevalence of fatigue varies slightly, fatigue seems
to be ubiquitous across IHD disease stages [1,3,4] and to persist despite
adequate medical treatment. Similarly, depressive symptoms are common
across disease stages, exerting a deleterious effect on health outcomes across
these stages [6-8]. In clinical practice, knowledge of the determinants of
fatigue and depressive symptoms is important for secondary prevention, given
that they may influence the clinical course of IHD and CHF [7-10]. However,
the determinants of symptoms of fatigue and depression are not clear yet.
In addition to IHD stage, personality may comprise a moderating factor
of fatigue and depressive symptoms. The distressed (type-D) personality has
been shown to predict fatigue in coronary artery disease (CAD) patients treated
with percutaneous coronary intervention (PCI) or coronary artery bypass graft
surgery [1,11], and the onset of depression in PCI patients [12,13], and is
associated with depression in patients with CHF [14]. Type-D personality is
defined as the tendency to experience negative emotions and to inhibit self-
expression [15]. The objectives of the current study were two-fold: 1) To
examine the effect of both the IHD stage and Type-D personality on fatigue
and depressive symptoms at 12-month follow-up; 2) To determine whether the
effect of type-D personality on fatigue and depressive symptoms is moderated
by IHD stage.
METHODS
Participants and study design
We included two different samples of cardiac patients to represent
ischemic heart disease stage, namely CAD patients treated with PCI to reflect
early-stage heart disease and ischemic CHF patients to represent end-stage
heart disease. The CAD patients comprised 419 consecutive patients with
stable or unstable angina, treated with PCI at the Erasmus Medical Center
Rotterdam using the paclitaxel-eluting stent as the default strategy. A more
detailed description of this sample has been provided elsewhere [1]. Of 419
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patients, 18 with a left ventricular ejection fraction (LVEF) 540% were
excluded, as this is an indication for CHF, leaving 401 patients for further
analyses.
The CHF sample comprised 105 ischemic patients visiting the heart
failure outpatient clinic of the TweeSteden Hospital, Tilburg, the Netherlands.
Inclusion criteria were systolic heart failure, LVEF 540%, and sufficient
understanding of the spoken and written Dutch language. Patients with
diastolic heart failure, age 280 years, myocardial infarction in the month prior
to inclusion, other life-threatening diseases, or insufficient knowledge of the
Dutch language were excluded. For this study, patients with non-ischemic
aetiologies were also excluded. Of 135 patients, 11 died prior to 12-month
follow-up and 19 were excluded due to missing questionnaire data at follow-up.
All patients completed questionnaires at baseline and at 12-month follow-up.
The study protocol was approved by the medical ethics committee of
the respective hospitals, and the study was conducted in accordance with the
Helsinki Declaration. All patients provided written informed consent.
Demographic and clinical variables
Demographic variables included gender, age, and marital status
(having a partner vs. not having a partner). Information on clinical variables,
that is, disease stage (CAD versus CHF), previous cardiac history (MI, PCI, or
CABG), hypertension, diabetes mellitus, smoking, and cardiac medication
(aspirin, beta-blockers, diuretics, ACE-inhibitors, and statins) was obtained
from the patients' medical records.
Symptoms of fatigue and depression
The Maastricht Questionnaire (MQ) was used to assess symptoms of
fatigue and depression [10]. The questionnaire consists of 21 items that are
answered on a three-point scale (0=no; 1=?; 2=yes). Research suggests that
the MQ predominantly assesses two symptom dimensions, namely fatigue and
depression [1,16]. We adopted the factor solution found in a previous study of
the PCI patients included in the current study [1], which is similar to that found
in a previous study [16]. The reliability of the subscales, as measured by
44
Cronbach's a, were .87 and .83, respectively. The MQ was administered both at
baseline and at 12-month follow-up.
Type-D personality
We used the Type-D Scale (DS14) to assess the distressed (type-D)
personality [17]. The scale consists of 14 items that are answered on a five-
point Likert scale from 0 (false) to 4 (true). Seven items tap negative
affectivity and seven items social inhibition (score range 0-28 for each
subscale). Type-D caseness is defined by a high score on both subscales, as
determined by a standardized cut-off score 210 [17]. The DS14 is a valid and
reliable scale, with Cronbach's a of .88 and .86 and 3-month test-retest
reliability of r =.72 and .82 for the negative affectivity and social inhibition
subscales, respectively [17]. Type-D personality is more than negative affect,
as it also takes into account how patients deal with this affect through the
inclusion of the social inhibition component [12,17]. The DS14 was
administered at baseline.
Statistical analyses
Discrete variables were compared with the chi-square test and
continuous variables with Student's t test for independent samples. A
McNemar's test was used to assess whether the prevalence of fatigue and
depression changed between baseline and 12-month follow-up. Univariable and
multivariable logistic regression analyses were used to examine the impact of
IHD stage and type-D personality on fatigue and depression at 12-month
follow-up. The moderating effect of IHD stage on the relationship between
type-D personality and fatigue and depression, respectively, was examined by
testing the interaction effect for type-D by IHD stage. Prior to analyses, the
fatigue and depression subscale scores were dichotomized using the highest
tertile to indicate clinically manifest symptoms. Dichotomization was used to




As displayed in Table 1, CAD patients were more likely to suffer from
hypertension and to be prescribed aspirin. On the other hand, CHF patients
were older and more likely to be males, smokers, and diabetics. In addition,
they were more likely to have a history of MI and CABG and to use B-blockers,
ACE-inhibitors, and diuretics.
The prevalence of type-D in the CAD patients was 24.4% versus 22.9%
in the CHF patients (p=.72). CAD patients with a type-D personality were more
likely to use diuretics as compared to CAD patients without type-D. CHF
patients with a type-D personality did not differ from non type-D CHF patients
on demographic and clinical baseline characteristics (Table 1). No other
statistically significant differences were found between type-D and non type-D
CHF and PCI patients, respectively, on demographic and clinical baseline
characteristics.
There was a significant decrease in the prevalence of symptoms of
fatigue over time (35.6% at baseline vs. 28.6% at 12-month follow-up,
p=.007). The prevalence of depressive symptoms was stable over time (36.6%
at baseline vs. 33.6% at 12-month follow-up, p=.93).
IHD stage, type-D and symptoms of fatigue and depression
In univariable analysis, IHD stage was neither associated with
symptoms of fatigue (p=.99) nor depression (p=.29) at 12-month follow-up. In
contrast, type-D personality was shown to predict both symptoms of fatigue
(OR=2.96; 95%CI 1.92-4.58, p<.001) and depression (OR=4.91; 95%CI 3.16-
7.65, p<.001) at follow-up. IHD stage neither moderated the relationship
between type-D personality and symptoms of fatigue (p=.70) nor depression
(p=.27), as shown by the non-significant interaction effects. Hence, type-D
personality had the same effect on fatigue and depression irrespective of IHD
stage, that is whether patients were diagnosed with CAD or with CHF (Figure
1).
Similarly, multivariable analysis revealed that type-D personality, but
not IHD stage, was an independent predictor of both symptoms of fatigue and
depression. There was a near significant effect for smoking and hypertension
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Table 1. Baseline characteristics
CAD-patients (N=401) CHF-patients (N=105)
Total Type-D Non type-D p Total Type-D Non type-D       p           p
(n=98) (n=303) (n=24) (n=81) (total)
Demographics
Female gender, n (%) 105 (26.2) 25 (25.5) 78 (25.9) .94 20 (19.0) 2 (8.3) 18 (22.2) .11 .03
Age, mean (SD) 62.9 (10.9) 61.9 (10.2) 63.1 (11) .33 66.6 (8.8) 69.4 (7.6) 65.7 (8.9) .09 .001
Married/partner, n (%) 331 (82.5) 82 (83.7) 248 (81.8) .76 82 (78.1) 20 (83.3) 62 (76.5) .48 .19Clinical
Smoking, n (%) 47 (11.7) 11 (11.2) 36 (12) .84 22 (21.0) 4 (16.7) 18 (22.2) .56 .01
Hypertension, n (%) 197 (49.1) 51 (52) 145 (48.2) .51 39 (37.1) 10 (41.7) 29 (35.8) .60 .03
Diabetes, n (%) 78 (19.5) 22 (22.4) 54 (17.9) .32 30 (28.6) 5 (20.8) 25 (30.9) .34 .04
History of MI, n (%) 154 (39.0) 36 (37.5) 117 (39.8) .69 85 (81.0) 21 (87.5) 64 (79) .35 <.001
History of PCI, n (%) 99 (24.7) 23 (23.5) 76 (25.2) .72 28 (26.7) 4 (16.7) 24 (29.6) .21 .68
History of CABG, n (%) 54 (13.5) 12 (22.2) 42 (14) .67 51 (48.6) 10 (41.7) 41 (50.6) .44 <.001Medication
4-blockers, n (%) 92 (22.9) 22 (22.4) 69 (22.9) .92 77 (73.3) 17 (70.8) 60 (74.1) .75 <.001
ACE-inhibitors, n (%) 34 (8.5) 11 (11.2) 23 (7.6) .27 80 (76.2) 18 (75) 62 (76.5) .88 <.001
Diuretics, n (%) 7 (1.7) 5 (5.1) 2 (0.7) .004 85 (81.0) 22 (91.7) 63 (77.8) .13 <.001
Statins, n (%) 304 (75.8) 71 (72.4) 232 (77.1) .35 73 (69.5) 18 (75) 55 (67.9) .51 .18
Aspirin, n (%) 386 (96.3) 95 (96.9) 289 (96) .68 62 (59.0) 14 (58.3) 48 (59.3) .94 <.001
Table 2. Predictors of symptoms of fatigue and depression at 12-month follow-up (multivariable analysis)
Fatigue Depression
Odds Ratio 95% CI                 p Odds Ratio 95% CI                 p
Variables of interest
IHD stagel .45 .14-1.41 .17 .30 .10-1.07 .07
Type-D personality 3.14 1.98-4.99 <.001 5.90 3.60-9.67 <.001
Covariates
Female gender 0.99 .58-1.68 .97 .36 .21-.61 <.001
Age .99 .97-1.01 ..29 .97 .95-.99 .01
Married/partner 1.58 .88-2.81 .13 1.48 .82-2.66 .19
Smoking
.85 .54-1.34 .49
1.75 . 95-3.24 .07 .94 .49-1.80 .85
Hypertension 1.48 .95-2.31 .08
Diabetes 1.21 .71-2.05 .48 1.14 .66-1.96 .64
History of MI 1.24 .77-1.97 .37 1.56 .97-2.52 .07
History of PCI 1.19 .73-1.95 .49 1.04 .63-1.72 .89
History of CABG 71 .42-1.41 .40 .79 .43-1.46 .44
11-blockers 1.14 .69-1.88 .60 1.23 .74-2.06 .42
ACE-inhibitors 1.29 .66-2.53 .45 2.51 1.23-5.11 .01
Diuretics 1.71 .58-5.06 .34 1.34 .42-4.27 .62
Statins 1.01 .61-1.65 .98 .39 .75-2.10 .39
Aspirin .56 .26-1.19 .13 .77 .35-1.71 .52
1  CHF =  1;  CAD  =  0
on symptoms of fatigue. Female sex, younger age, and use of ACE-inhibitors
were associated with an increased risk of depressive symptoms at 12-month
follow-up. Near significant effects were found for IHD stage and history of MI
(Table 2). The effect of type-D personality on symptoms of fatigue (OR=1.87;
95%CI 1.12-3.15, p=.02) and depression (OR=3.57; 95%CI 2.09-6.10,
p<.001) remained significant after controlling for symptom levels at baseline.
Figure 1. The effect of type-D personality on (A) symptoms of fatigue and (B)
symptoms of depression at 12-month follow-up stratified by IHD stage
(A)
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The prevalence of symptoms of fatigue and depression in IHD is well
documented [19-22]. Increased levels of fatigue and/or depression have been
found in CAD [23-26], post-MI [2,3,6], and CHF patients [4,5,8], but to our
knowledge there has been no systematic comparison between IHD stages and
psychological symptom levels. Therefore, the primary aim of the current study
was to examine the effect of IHD stage on fatigue and depressive symptoms at
12-month follow-up. Ischemic CHF-patients were used to reflect end-stage
IHD, whereas PCI patients were used to reflect early-stage IHD. We found that
IHD stage predicted neither symptoms of fatigue nor symptoms of depression.
This may seem counter-intuitive, since CHF patients generally have poorer
prognosis as compared to CAD patients [27], and one may expect this to be
accompanied by increased psychological symptom burden. However, the
physiological course of a disease may not be on par with the psychological
course. Earlier studies have described adaptive psyc..ological mechanisms in
chronic illnesses [28,29], which may serve as an explanation for the current
findings. On average, CHF patients have a longer and more severe cardiac
history as compared to CAD patients. Therefore, they may be better
accustomed to the disease, which in turn could mask the objectively increased
physical deterioration.
Previous research has shown that type-D personality is associated with
symptoms of fatigue and depression in patients with CAD [9,10]. This was also
confirmed in the current study. In addition, we found that the effect of type-D
personality on symptoms of fatigue and depression was the same for CHF and
CAD patients, and that this effect was independent of other demographic and
clinical risk factors.
The present findings hold some important implications. First, clinically
manifest symptoms of fatigue and depression were equally prevalent in CHF
and CAD patients despite a marked difference in IHD stage. This suggests that
clinicians should be cautious when attributing self-reported symptoms to the
disease itself, with psychological factors likely playing an important role. We
found that type-D personality rather than IHD stage was associated with
symptoms of fatigue and depression. The findings of the current study and
other studies [30-32] indicate that a personality approach may be
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advantageous in terms of identifying patients at high risk for increased
psychological symptomatology. It is important to emphasize that this should
not be limited to type-D personality, fatigue, and depression, but that we
should focus on a broader spectrum of behavioral and psychological factors
[33]. Therefore, future studies are warranted that give a more in-depth insight
into the differences in psychological make-up of patients at different stages of
CAD. To optimize risk stratification in clinical practice, future studies should
also focus on identifying symptoms that are most cardio-toxic in terms of
predicting clinical outcome, in line with a previous study in which we showed
that hopelessness was the most cardio-toxic depressive symptom [34].
This study had a number of limitations. First, we only focused on
symptoms of fatigue and depression. Other psychological factors might be
important as well, such as anxiety [33,35]. Second, our results may not be
generalizable to other cardiac patient groups, for example CABG or post-MI
patients. Third, retrospective bias may have influenced the measurement of
symptoms of fatigue and depression since patients were asked to report
distress levels in the period preceding the administration. Fourth, we did not
have information on educational level and co-morbid medical illness. Strengths
of the current study were its prospective design and the use of validated and
reliable psychological measures.
In conclusion, type-D personality but not IHD stage predicted
symptoms of fatigue and depression at 12-month follow-up. In addition, IHD
stage did not moderate the effect of type-D on symptom levels. Careful
consideration of patients' self-reported symptoms is therefore warranted. CAD
research and clinical practice may benefit by adopting a personality approach in
order to explain individual differences in symptom presentation and to identify
patients at high-risk of adverse health outcomes.
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Vital exhaustion and cardiovascular prognosis in myocardial
infarction and heart failure: Predictive power of different
trajectories
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ABSTRACT
Aim: We examined the different trajectories of vital exhaustion (VE) over a 12-
month period and their impact on prognosis in a sample of myocardial
infarction (MI) and chronic heart failure (CHF) patients. Methods: Consecutive
MI (N=407) and CHF patients (N=297) were assessed at baseline, 3- and, 12-
month follow-up for symptoms of VE. Latent growth mixture modelling was
used to examine the course of VE over time. The combined clinical endpoint
was defined as cardiac hospital readmission or death. Results: Four distinct
trajectories for VE were found: low VE, decreasing VE, increasing VE, and
severe VE. Sex, marital status, left ventricular ejection fraction, psychotropic
medication, sample group (CHF vs. MI), and depressive symptoms were
associated with VE, varying according to classes. The mean follow-up period
was 25.3 months in which 34.7% of the patients experienced an event.
Multivariate Cox regression showed that patients in the increasing VE class
(HR=1.16; 95%CI 1.58-3.61, p=.01), and the severe VE class (HR=1.69;
95%CI 1.31-2.64, p=.02) had an increased risk for adverse cardiovascular
events as compared to low VE class. Decreasing VE was not related to
prognosis (HR=.97; 95%CI .66-1.69, p=.81). Conclusions: VE trajectories
varied across cardiac patients, and had a differential effect on cardiovascular
outcome. Increasing VE, and severe VE classes were predictors of poor
prognosis. These results suggest that identification of cardiac patients with an




Vital exhaustion (VE) is a frequently observed phenomenon in patients
with coronary artery disease and chronic heart failure (CHF) (1-3). The most
commonly used definition of VE is that of unusual tiredness, increased
irritability, and feelings of demoralization (4). VE has been associated with a 2
to 3 fold increased risk of mortality and morbidity in patients with coronary
artery disease (2,3,5), and several potential biological pathways have been
identified to explain this association. VE has been shown to relate to increased
lipid metabolism (6), hypocortisolemia (7,8), reduced fibrinolytic capacity
(9,10), parasympathetic withdrawal (11), and increased levels of cytokines,
e.g. IL-6 (12,13).
The 21-item Maastricht Questionnaire (MQ) is often used to assess VE
(4). Previous studies have shown that VE as measured by the MQ is not similar
to symptoms of fatigue, but additionally comprises factors such as depressive
symptoms, sleep problems, and lack of concentration (3,14-16). It has been
shown that VE is prevalent in both patients with myocardial infarction (MI) and
CHF patients (3,17), but it is not clear whether levels of VE differ across these
patient groups. Given disease stage, VE might also be differently related to
cardiovascular prognosis.
Although previous studies have stressed the importance of VE in
cardiac disease (3,18-20), there is a paucity of research on the evolution
and/or persistence of VE. Patients may have varying courses of VE and, hence,
potentially differential risks of adverse health outcomes. Knowledge of VE
trajectories, their clinical and psychological characteristics, and their prognostic
impact might allow for the identification of high-risk cardiac patients who may
need additional clinical care above and beyond the standard medical
management of the disease.
Since the course of VE has not been studied in cardiac patients, the
current study's objective was to examine 1) the course and characteristics of
VE during a 12-month period, and 2) their impact on cardiovascular prognosis




In order to cover both acute and chronic cardiac disease, we combined
two different samples. A sample of patients who recently had a myocardial
infarction (MI) was included to reflect acute cardiac disease, whereas a sample
of patients suffering from chronic heart failure (CHF) was included to reflect
chronic cardiac disease. This resulted in a total sample of 704 patients. The MI
patients comprised 407 patients that participated in the DepreMI study (21),
which is a naturalistic follow-up study of the impact of depressive symptoms on
cardiac prognosis in MI patients in four hospitals in the North of The
Netherlands. Patients admitted for an MI between September 1997 and
September 2000 were included and followed until April 2002. Patients received
usual aftercare for their MI and depressive symptoms. Of the 528 patients that
were initially included, 60 patients were lost during follow-up (i.e. refusal,
death), and 61 patients had missing questionnaire data on 2 or more
measurement points, leaving 407 patients for the present study. Inclusion
criteria were a) chest pain for at least 20 minutes, b) creatinine phosphokinase
levels 100% above normal or creatinine phosphokinase MB levels above 10%,
and c) presence of new pathological Q waves on the electrocardiogram in at
least two leads. Exclusion criteria were life expectancy of less than a year
(because of noncardiac condition), too poor physical condition according to
hospital staff, cognitive dysfunction, inability to speak or read Dutch,
occurrence of an MI in patients admitted for another reason, and follow-up
visits scheduled in a nonparticipating hospital.
The CHF patients comprised 297 consecutive patients with systolic
heart failure and a left ventricular ejection fraction (LVEF) 540%, visiting the
heart failure outpatient clinic of the TweeSteden hospital, Tilburg, the
Netherlands. Of the 378 patients that were initially included, 44 patients died
during the first year of the study, and 37 patients had missing questionnaire
data on 2 or more measurement occasions, leaving 297 patients for the
present study. Patients with diastolic heart failure, age 280 years, myocardial
infarction in the month prior to inclusion, other life-threatening diseases, and
no or insufficient understanding of spoken and written Dutch language were
excluded beforehand.
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Patients completed a questionnaire at baseline, 3-month follow-up, and
12-month follow-up. The study protocol was approved by the institutional
review boards of the participating hospitals, and was conducted conform to the
Helsinki Declaration. Every patient provided written informed consent.
Vital exhaustion
VE was assessed by the 21-item Maastricht Questionnaire (4). Each
item is originally rated according to a three-point scale (Yes=0; 7=1; No=2),
and a total score was calculated by summing the answers. The reliability of the
total scale is good with Cronbach's alpha of 0.89 (5). Frequency analysis on
every single item revealed that the question mark category was rarely used
(<10%). Therefore, we decided to divide the total scores by a factor 2 and to
round up to integers at a zero point five level. Hereby, we considered these
scores as count variables of the number of VE symptoms. From a psychometric
perspective, this is more appropriate than using the scores as a continuous
variable.
Symptoms of depression
Symptoms of depression were measured by means of the Beck
Depression Inventory (BDI) (22). Each item is rated on a 0-3 scale. A total
score is obtained by summing together all the items. The BDI is a reliable and
well-validated measure of depressive symptomatology (23), and is the most
widely used self-report measure of depression. This subscale was dichotomized
using the standardized BDI cut-off score of 210 versus BDI scores <10.
Demographic and clinical variables
Demographic variables included sex, age (<60 yrs vs. 260 yrs), and
marital status (partner vs. no partner). Clinical variables comprised smoking
status, LVEF (<40% vs. 240%), previous MI, diabetes mellitus, and cardiac
medication. Information on clinical variables was obtained from the medical
records and from the treating cardiologist or heart failure nurse.
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Cardiovascular prognosis
The combined clinical endpoint was defined as cardiovascular hospital
readmission or cardiovascular death. Information on potential end points was
collected from hospital records and the patient's primary care physician. Mean
follow-up duration was 25.4 months (SD=13.3).
Statistical analyses
Latent class analysis (LCA) was employed to examine trajectories of VE
symptoms in cardiac patients over a 12-month period (24). A latent growth
Poisson mixture model was fitted to identify classes of individuals following
similar patterns of behavior over time. The model assumes unobserved latent
variables to explain the associations among observed scores, and can be seen
as a categorical equivalent of factor analysis. One of the problems with fitting
these types of latent class models is that the categorization into classes is
dominated by the overall symptom levels making it less likely that the model
picks up symptom changes. A way to overcome this problem is the inclusion of
a random intercept (25).
To determine the optimal number of trajectories, the Aiken Information
Criterion 3 (AIC3) was used, with a lower AIC3 indicating a better fit. However,
a difference of less than 3 will favor the least complex model. Recent studies
have shown that AIC3 is a better criterion than BIC and AIC in determining the
number of latent classes in LC models (26,27).
For comparison between classes we used the Chi-square test for
discrete variables. Adjusted Standardized Residuals (ASRs) were used to
identify groups responsible for significant differences. A residual greater than
2.0 was taken to indicate a significantly higher frequency, and a residual less
than -2.0 was considered to indicate a significantly lower frequency, than
expected if the independence hypothesis was true (28).
Multivariate Cox proportional hazards regression was used to assess
whether VE trajectories predicted the combined end-point of cardiovascular
readmission or death. In the regression model, we included age, gender,
marital status, smoking status, diabetes mellitus, previous MI, disease severity
(LVEF), beta blockers, calcium antagonists, aspirin, psychotropics, and
depressive symptoms because of their relation with cardiovascular prognosis
62
(29-36). The LCA was performed with the program Latent GOLD 4.5 (24). All
other data were analyzed using SPSS 15.0.1 for Windows. A similar approach
has previously been used in MI- (37), PCI- (38), and PAD patients (39).
RESULTS
Trajectories of vital exhaustion
Figure 1 displays the four distinct developmental trajectories for vital
exhaustion. The AIC3 improved from one class of VE (AIC3 = 11526) to four
classes of VE (AIC3 = 11315), whereas a relative decline was observed in the
five class model (AIC3 = 11322). Compared to the three class model (AIC3 =
11323), the four class model achieved a significant improvement in fit. The
four class model was therefore adopted for further analysis.
Figure 1. Observed trajectories of vital exhaustion
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The first class (16.8% of the sample) was classified as the low VE
group (intercept=0.57, p<.001; slope= -0.06, p<.001), and had low levels of
VE on all time points. The first class was used as a reference category. The
second class (29.1%) was characterized by a decrease in VE symptoms over
time (intercept=1.81 , p<.001; slope= -0.06, p<.001). The third class (8.1%)
was described as increasing VE (intercept=1.30, p<.001; slope= 0.03, p=.09).
Finally, the fourth class (46.0%) was classified as severe VE (intercept=2.38,
p<.001; slope= -0.0023, p=.34) with high levels of VE on all time points.
Characteristics of vital exhaustion trajectories
There were a number of differences in demographic, clinical, and
psychological characteristics at baseline as a function of VE class (Table 1).
Table 1. Baseline characteristics stratified by vital exhaustion class*
Variable Total Low vital Decreasing Increasing Severe vital    p-
exhaustion vital vital exhaustion value
exhaustion exhaustion
% (n) (n=118) (n=205) (n=57) (n=324)
Male sex 76.6 (539) 87.3 (103) 79.0 (162) 93.0 (53) 68.2 (221) <.001
Age260 62.9 (443) 55.1 (65) 67.3 (138) 61.4 (35) 63.3 (205) .18
No partner 19.2 (135) 11.0 (13) 18.0 (37) 12.3 (7) 24.1 (78) .007
Smoking 38.2 (269) 40.7 (52) 32.7 (66) 50.9 (29) 38.9 (126) .06
Previous MI 29.8 (210) 21.2 (25) 31.2 (64) 22.8 (13) 33.3 (108) .05
Diabetes 15.2 (107) 11.9 (14) 16.1 (33) 5.3 (3) 17.6 (57) .07
Heart failuret 42.2 (297) 37.3 (44) 39.5 (81) 26.3 (15) 48.5 (157) .005
LVEF<40% 56.0 (394) 50.0 (59) 54.1 (111) 45.6 (26) 61.1 (198) .05
Beta blocker 72.5 (510) 78.8 (93) 69.8 (143) 75.4 (43) 71.5 (231) .32
Calcium Ant. 17.5 (123) 19.5 (23) 16.6 (34) 19.3 (11) 17.0 (55) .89
Aspirin 67.3 (474) 66.1 (78) 69.3 (142) 75.4 (43) 65.1(211) .42
Psychotropics 8.1 (57) 1.7 (2) 4.4 (9) 1.8 (1) 6.4 (45) <.001
Depr. Sympt. 27.6 (194) 3.4 (4) 9.3 (19) 5.3 (3) 51.9 (168) <.001
* Numbers in bold represent an absolute adjusted standardized residual > 2.0
t CHF group as compared to the MI group
Departure from independence was most pronounced in the extreme VE groups,
(Table 1; numbers in bold). Patients in the low VE group were more likely to be
male (ASR=3.0), and to have a partner (ASR= -2.5). In addition, they were
less likely to be on psychotropics (ASR= -2.8), and to be depressed (ASR= -
6.4). Patients in the decreasing VE group were less likely to be depressed
(ASR= -7.0). Other deviations were not observed in this class. Patients in the
increasing VE group were more likely to be male (ASR= 3.1), and MI patient
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(Figure 2). Furthermore, these patients were less likely to be depressed (ASR=
-3.9). Finally, patients in the severe VE group were more likely to be female
(ASR= -4.8), alone (ASR=3.0), on psychotropic medication (ASR=5.2),
depressed (ASR= 13.3), and to have decreased LVEF (ASR=2.5). As displayed
in figure 2, CHF patients were more likely to be in the severe VE group as
compared to MI patients (ASR=3.1), independent of LVEF.
Figure 2. Percentage of patients per VE class stratified by sample group & LVEF
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Trajectories of vital exhaustion and cardiovascular prognosis
The mean follow-up period was 25.4 months (SD=13.3). During this
period, 244 patients (34.7%) experienced an adverse cardiovascular event.
Lower LVEF was associated with an increased risk for adverse cardiovascular
events (Table 2). Previous MI showed a trend towards significance.
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Univariate Cox regression analysis revealed that the event rate in the
increasing VE class, and the severe VE class was significantly higher as
compared to the low VE class (Figure 3). In multivariate analysis, increasing VE
and severe VE remained significant predictors of adverse cardiovascular events
(Table 2). Compared to the low VE group, patients in the increasing VE class
(HR=1.16; 95%CI 1.58-3.61, p=.01), and in the severe VE class (HR=1.69;
95%CI 1.31-2.64, p=.02) had an increased risk for cardiovascular events.
Patients in the decreasing VE class had a similar risk for cardiovascular events
(HR=.97; 95%CI .66-1.69, p=.81) as compared to the low VE class. Adding
sample group (MI vs. CHF) as a predictor did not significantly alter the results
presented in Table 2.
Table 2. Trajectories of vital exhaustion and cardiac prognosis (multivariate)
Variable HR 95%CI p-value
Male sex .97 .71-1.32 .82
Age260 1.16 .86-1.58 .33
Having no partner .95 .69-1.31 .76
Smoking 1.08 .81-1.43 .61
Previous MI 1.32 .99-1.75 .06
Diabetes 1.28 .93-1.77 .14
LVEF<40% 1.94 1.36-2.75 <.001
Beta blocker .80 .60-1.06 .13
Calcium antagonists .81 .56-1.18 .27
Aspirin .84 .63-1.11 .21
Psychotropic medication 1.26 .84-1.91 .27
Depressive symptoms 1.13 .82-1.54 .45
Decreasing vital exhaustion 1.06 .66-1.69 .81
Increasing vital exhaustion 2.04 1.15-3.61 .01
Severe vital exhaustion 1.69 1.08-2.64 .02
DISCUSSION
To our knowledge, this is the first study to examine the course of vital
exhaustion in a combined sample of MI and CHF patients. We found four
distinct trajectories for VE: (i) low levels of VE on all time points; (ii)
decreasing levels of VE over time; (iii) increasing levels of VE over time; (iv)
high levels of VE on all time points. Sex, marital status, LVEF, psychotropic
medication, sample group (CHF vs. MI), and depressive symptoms were
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Figure 3. Cardiovascular event rate stratified by VE class (univariate)
p =.001                                    1
1
P=.03
40-                                    1
22










0             -
Low VE Decreasing VE Increasing VE Seve re  VE
associated with VE, varying according to classes. Multivariate Cox regression
showed that patients in the increasing VE class and the severe VE class had an
increased risk for adverse cardiovascular events as compared to low VE class.
Patients in the decreasing VE class had a similar risk for cardiovascular events
as compared to the reference category.
The results of the present study advocate the use of latent growth
mixture modeling to study the course of symptom levels over time which has
also been argued in other studies (21,37-39). Similar to our study, these
investigations have also found support for multiple rather than one trajectory,
although they studied depression (21,37,39) and anxiety (38). Our approach
was however a bit different from the previous studies because 1) we allowed
the error terms to vary between classes which was not the case in the study of
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Kaptein et al. (21), and 2) we included a random intercept to remove the
overall response level effects (25). In our opinion, both adjustments improved
the model specification considerably, as was demonstrated by higher AIC3
values (not reported) in VE models with fixed error terms and without a
random intercept.
The most important finding is that two trajectories of VE were
associated with an increased risk of cardiovascular events, representing chronic
severely exhausted patients and patients in which levels of VE increased during
the follow up year. Of interest, MI patients were relatively more present in the
increasing VE class as compared to CHF patients. Our findings thus suggest
that a significant number of patients after a MI do not fully recover but
deteriorate over time, which in the current study is expressed as an increase in
the number of VE symptoms and subsequently an increased cardiac risk.
Patients in this class might reflect a group of patients that do not respond to
standard treatment procedures. These findings appear to be consistent with
previous observations by Carney (40), De ]onge (41) and Kaptein (21) who
found that persistence of depressive symptoms (despite treatment) was
associated with an increased cardiac risk. Of note, in those studies depression
was assessed with the BDI, in which somatic symptoms of depression (such as
fatigue and sleeping difficulties) are relatively overrepresented. In contrast,
CHF patients were relatively more present in the severe VE class. CHF patients
on average have a longer and more severe cardiac history and did not
experience a recent acute coronary syndrome. CHF patients may therefore
display a more stable pattern of vital exhaustion over time. As a consequence,
the most vulnerable class of CHF patients is characterized by a chronic, severe
level of VE. Thus, the most vulnerable MI and CHF patients may differ in their
patterns of VE.
From a clinical point of view, knowledge about factors characterizing
trajectories that display changes over time is important as they point to targets
for intervention. Importantly, the findings of the present study indicate that VE
trajectories are differently related to an increase of adverse cardiovascular
events. In a previous study, we have shown that symptom profiles of vital
exhaustion in CHF patients, measured at a single time point, were associated
with rehospitalization (3). It would be interesting to study these symptom
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profiles using a latent growth mixture modeling approach, and examine the
effect of symptom profile trajectories on cardiovascular prognosis.
Furthermore, in the multivariate Cox model, we controlled for depressive
symptoms measured at baseline, and demonstrated that trajectories of VE
independently predicted our outcome measure. The potential effects of
depressive symptoms at later time points were ignored. It would be worthwhile
to investigate the distinctiveness of VE and depression using a joint trajectory
modeling approach (42) providing full control of each others effects on
outcome measures. Generally, large-scale studies should give a more in-depth
insight into the differential effect of the VE trajectories on cardiovascular
prognosis.
This study has a number of limitations. First, the cardiologist or heart
failure nurses asked patients to participate in the study, and this interaction
pattern might have influenced patient selection. Second, the examined
predictors of the VE trajectories were only assessed once. Given that, for
example, depressive symptoms were identified as an independent predictor of
persistent VE, it is possible that these levels may be attributed to persistent
depressive symptoms, rather than baseline levels. Nevertheless, the strengths
of the current study were the repeated assessment of VE over time, the
prospective design examining the course of VE over time using a state-of-the-
art modeling approach, and the use of a semi-objective medical outcome.
Finally, we used a reliable and valid measure of vital exhaustion.
In summary, we found four distinct trajectories for vital exhaustion.
Several predictors, varying according to classes, could be identified with sex,
marital status, LVEF, psychotropic medication, sample group (CHF vs. MI), and
depressive symptoms being the most prominent ones. Increasing VE class, and
the severe VE class had an increased risk for adverse cardiovascular events as
compared to low VE class. Patients in the decreasing VE class did not have an
increased risk for adverse events as compared to the reference category.
Future studies are warranted to confirm these findings, given that this
was the first study to examine the course of VE in cardiac patients. The results
of the present study may help identify distinct groups of patients with
potentially differential risks of adverse health outcomes, guide future
interventions, and therefore be valuable for both research and clinical practice.
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ABSTRACT
Objective: To examine the role of clinical and psychological characteristics as
predictors of fatigue in CHF. Background: Little is known about predictors of
fatigue in CHF . Next to heart failure characteristics, depressive symptoms and
type-D personality may explain individual differences in fatigue. Methods: At
baseline, 136 CHF outpatients (age580) completed a questionnaire to assess
depressive symptoms, type-D personality and cardiac symptoms. At one-year
follow-up, they completed the Dutch Exertion Fatigue Scale and the Fatigue
Assessment Scale to assess symptoms of fatigue. Medical information was
obtained from the patients' medical records. Results: Exertion fatigue and
general fatigue were identified as different manifestations of fatigue. We found
that exertion fatigue at 12-month follow-up was predicted by decreased
exercise capacity (B=-.35; p<.001), dyspnoea (B=.24; p=.002), hypertension
(B=.16; p=.03), and depressive symptoms (B=.16; p=.05). In contrast,
general fatigue at 12-month follow-up was predicted by dyspnoea (B=.24;
p=.003), depressive symptoms (B=.27; p<.001), type-D personality (B=.17;
p=.03), and sleep problems (B=.20; p=.01). Together, these variables
explained 32 and 37 percent of the variance, respectively. Conclusion: The
present study showed that fatigue was related to both clinical and psychological
characteristics. The use of this knowledge may lead to a better understanding
and treatment of the clinical manifestations of fatigue in CHF.
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Introduction
Chronic heart failure (CHF) is accompanied by severe symptoms and
poor prognosis. Recent studies have underlined the importance of symptoms in
CHF, both in terms of prognosis [1,2] and quality of life [3]. One poorly
understood symptom of CHF is fatigue.
Fatigue is often rated as one of the most disabling symptoms in chronic
heart failure [4], however, little is known about its predictors [1,5,6]. One
small study in women with CHF found that only symptoms of dyspnoea
predicted fatigue [6]. Clearly, more studies are needed to give a more in-depth
insight into the variables that predict fatigue. In addition, previous research
has shown that different forms of fatigue are relevant to CHF patients; these
are exercise related symptoms of fatigue, and general feelings of fatigue which
are not necessarily related to exercise [7]. Accordingly, it is necessary to
examine the dimensionality of fatigue before relating it to other variables.
Haemodynamically, symptoms of fatigue during exercise are thought to
arise from failure of muscle perfusion due to an inadequate rise in cardiac
output. However, many studies have shown that there is no relation between
cardiac performance and exercise performance [8,9]. Recently, it has been
suggested that chronic, low grade haemodynamic stress as seen in CHF, may
lead to dominance of catabolic processes. This in turn leads to skeletal
myopathy, causing the sensation of fatigue [10]. Future studies should aim to
demonstrate to what extent skeletal myopathy is able to explain individual
differences in fatigue.
Besides physiological explanations for symptoms of fatigue in CHF,
psychological factors should also be taken into account. Depressive symptoms
have previously been associated with fatigue in CHF [11,12]. However, the role
of personality as a predictor of fatigue in CHF has received little attention up to
now. A study in patients with ischaemic heart disease revealed that patients
with a type-D personality, a joint tendency toward negative affectivity and
social inhibition, were more likely to report symptoms of fatigue and
exhaustion [13]. Comparable results were found in a related set of personality
variables in patients with multiple sclerosis [14]. Therefore, it seems important
to examine the role of personality as a predictor of fatigue in CHF patients as
well.
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The aim of the present prospective study was (1) to examine the
nature of fatigue, and (2) to examine the role of clinical and psychological
characteristics as predictors of fatigue in CHF.
Methods
Participants
The sample included 136 CHF patients visiting the heart failure
outpatient clinic of the Twee Steden Ziekenhuis, Tilburg, the Netherlands. As
displayed in Table 1, the majority of subjects was male, married, unemployed,
non-smokers, and not academically educated. About half the sample was
classified as NYHA-class III/IV, had a cardiac history, and ischaemic CHF. Only
a minority of the sample were overweight and anaemic. Co-morbidities that
were most common included hypertension, diabetes mellitus, and peripheral
artery disease. Diuretics, ACE-inhibitors, and beta-blockers were the most
prescribed medications.
Inclusion criteria were defined as systolic heart failure, LVEF 5 40%,
and sufficient understanding of spoken and written Dutch language. Exclusion
criteria were defined as diastolic heart failure, age 2 80 years, myocardial
infarction in the month prior to inclusion, other life-threatening diseases,
clinical signs of an acute infection, use of anti-inflammatory medication.
Patients filled out questionnaires with regard to personality, dyspnoea,
and depressive symptoms at baseline, and fatigue at twelve-month follow-up.
All patients participated voluntarily and signed informed consent. The study
protocol was approved by the medical ethics committee of the St. Elisabeth
Hospital, Tilburg, the Netherlands.
Symptoms of fatigue
Previous research has shown that general fatigue does not necessarily
have a relationship with exertion [7]. Therefore, separate measures were used
to assess exertion fatigue and general fatigue, respectively. Exertion fatigue
may be defined as fatigue directly related to the performing of activities in daily
living [7], whereas general fatigue has been defined as an overwhelming,
sustained sense of exhaustion and decreased capacity for physical and mental
work [15].
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Table 1. Baseline characteristics
Age: Mean (SD) 65.6 (8.5)
Male gender 104 (76.5%)
Having a partner 106 (77.9%)
No academic education 117 (86.0%)
Unemployed 113 (83.1%)
NYHA-class III/IV 73 (53.7%)
LVEF: Mean (SD) 30.0% (6.9)
Ischemic aetiology 72 (52.9%)





Renal insufficiency 17 (12.5%)
Liver disease 6 (4.4%)
Diabetes mellitus 34 (25%)
Hypertension 49 (36.0%)







Beta blocker 91 (66.9%)
Statins 67 (49.3)
Aspirin 63 (46.3%)
Anaemia (Hb5120 9/L) 27 (19.9%)
BMI: Mean (SD) 28.3 (4.9)
BMI: body mass index; LVEF: left ventricular ejection fraction.
* MI, angina, PCI, or CABG.
The Dutch Exertion Fatigue Scale (DEFS) assesses exertion fatigue by
means of 9 items [10]. Items are answered with five response alternatives
ranging from 0 (no) to 4 (yes). Chronbach's alpha is high (a=.91). The Fatigue
Assessment Scale (FAS) was used to assess symptoms of general fatigue [16].
This questionnaire consists of 10 items, which are answered on a 5-point Likert
scale, ranging from 1 (never) to 5 (always). The reliability of this instrument is
high (a=.90).
Dyspnoea, chest pain, & sleep problems
Cardiac symptoms were measured by means of the 12-item Somatic
complaints subscale of the Health Complaints Scale (HCS) [17]. Items are
answered on a 5-point Likert scale, ranging from 0 (not at all) to 4
(extremely). The items measuring chest pain, shortness of breath, and sleep
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problems were used as separate subscales. The items measuring fatigue were
excluded.
Symptoms of depression
Symptoms of depression were measured by means of the Beck
Depression Inventory (BDI) [18]. Each item is rated on a 0-3 scale. The BDI is
a reliable and well-validated measure of depressive symptomatology [19,20],
and is the most widely used self-report measure of depression. Since the
somatic items of the BDI may be confounded by symptoms of fatigue, only the
cognitive-affective subscale was used [21]. Because of non-normality, the
subscale was dichotomized at the highest tertile.
Type-D personality
Type-D personality was measured by means of the DS14 [22]. This 14-
item questionnaire comprises two subscales, Negative Affectivity and Social
Inhibition, each consisting of 7 items. The items are answered on a 5-point
Likert scale, ranging from 0 (false) to 4 (true). Negative affectivity refers to the
tendency to experience negative emotions across time/situations, whereas
social inhibition refers to thetendency to inhibit the expression of
emotions/behaviours in social interactions to avoid disapproval by others.
Previous studies in coronary patients have shown that type-D's are at risk for a
wide range of adverse health outcomes, including mortality [23], morbidity
[24], and mood status [25].
A standardized cut-off score of 210 on both subscales classifies
subjects as a type-D personality [22]. Initially, this cut-off corresponded to a
median split of both subscales which resulted in a prevalence rate between 27
and 31 percent of type-D's among patients with coronary heart disease. In the
present study, the prevalence rate of type-D was 26%, which is in accordance
with the rates mentioned above. Both scales have good internal validity (a=.88
for Negative Affectivity and a=.86 for Social Inhibition).
In a sample of coronary patients who underwent cardiac rehabilitation,
both negative affectivity and social inhibition were relatively stable over a 3
month period (test-retest r=.82 for Negative Affectivity and  r=.72 for Social
Inhibition), and DS14 mean scores did not change significantly over time. In
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contrast, measures of mood and health status did show significant changes
over this 3 month period [22], suggesting that a patients' score on the DS 14 is
relatively independent from changes in mood and health status.
Additionally, it has been shown that type-D is different from established
personality constructs like neuroticism and extraversion, even though they are
related. Negative affectivity only shared 46% of its variance with neuroticism,
and social inhibition only shared 35% of its variance with extraversion [22].
Although more research on its situational stability is needed, the findings
support the validity of type-D as a personality construct.
Demographics and clinical variables
Demographics included sex, age, educational level, marital status, and
employment status. Medical variables, obtained from patients' medical record
included Left Ventricular Ejection Fraction (LVEF), functional class (NYHA-
classification), aetiology of heart failure, co-morbidities, cardiac history, and
prescribed medications. Exercise capacity was measured by means of the six-
minute walking test (walking small circuits of 52 meters), which was carried
out within the hospital as part of this study. Patients were instructed to walk at
a normal pace, and to continue walking until they were told to stop or until
they experienced too many adverse symptoms. Patients were not encouraged
to walk as far as possible because the test was meant to reflect daily life
exercise capacity.
Statistical Analyses
Principal component analysis (PCA) with oblimin rotation was used to
determine whether general fatigue and exertion fatigue could be distinguished
from each other. Factors with an eigenvalue > 1 were retained according to
Kaiser's criterion. KMO and Bartlett's test of sphericity were used as fit indices.
Prior to further statistical analyses, educational level, marital status,
employment status, NYHA-class, aetiology of heart failure, co-morbidities,
haemoglobin levels, and cardiac history were recoded into dichotomous
variables.
Associations with fatigue at 12-month follow-up were examined with Pearson's
product moment correlation coefficients for continuous variables, and with
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point-biserial correlations for discrete variables. Factors that were significantly
associated with fatigue at 12-month follow-up were entered into a stepwise
regression procedure. Regression analyses were performed for each dimension
of fatigue. In order to examine the generalizability of the models obtained by
the stepwise procedure, the population cross-validation coefficient Rcz was
computed using Steins formula [26]. It has been shown that the Rcz is a far
more accurate correction for shrinkage than the adjusted R2. In addition, Rcz is
also preferred over empirical cross-validation [27,28].
RESULTS
Nature of fatigue
Principal component analysis on the two fatigue scales at 12-month
follow-up revealed a 3-factor solution (Table 2). KMO (0.89) and Bartlett's test
of sphericity (%2 (171, N=136) = 1580.2, p<.001) indicated that PCA was
adequate for this data. Two specific components were found, i.e. exertion
fatigue and general fatigue. The nonspecific third factor was excluded from
further analysis. Items with component loadings >.40 and Across-loadings
<.20 were used to construct subscales. Accordingly, 7-item subscales of
exertion fatigue (a=.89) and general fatigue (a=.90) were formed,
respectively. Exertion fatigue and general fatigue were moderately correlated
(r=.55; P<.001).
Predictors of fatigue
Significant univariate correlates of exertion fatigue and general fatigue
at 12-month follow-up are displayed in Table 3. Variables with a bivariate
correlation 2.30 with respect to exertion fatigue were exercise capacity, NYHA-
class, dyspnoea, cardiac pain, and depressive symptoms. A correlation 2.30
with general fatigue was found for sleep problems, dyspnoea, cardiac pain,
depressive symptoms, and type-D personality.
Stepwise regression analysis revealed that exertion fatigue at 12-
month follow-up was best predicted by exercise capacity, dyspnoea,
hypertension, and depressive symptoms. Together, these four variables
explained 32 percent of the variance in exertion fatigue. General fatigue at 12-
month follow-up was best predicted by dyspnoea, depressive symptoms, type-
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Table 2. Dimensions of fatigue at 12-month follow-up
Item Content                                                 Fl    F2    F3
DEFS 9 It is fatiguing for me to go to a birthday party .89
DEFS 7 It is fatiguing for me to hoover .89
DEFS 8 It is fatiguing for me to visit someone .85
DEFS 6 It is fatiguing for me to clean up my household waste .81
DEFS 5 It is fatiguing for me to shop .72
DEFS 3 It is fatiguing for me to take a shower standing .65
DEFS 1 It is fatiguing for me to walk 10 minutes .60
DEFS 2*   It is fatiguing for me to walk 30 minutes .50 -.35
DEFS 4*   It is fatiguing for me to go up- and downstairs .46 -.35
FAS 6 I have problems starting things -.83
FAS 5 Physically, I feel exhausted -.80
FAS 8 I feel no desire to do anything -.79
FAS 3 I don't do much during the day -.73
FAS 1 I am bothered by fatigue .30 -.67
FAS 9 Mentally, I feel exhausted -.66 -.46
FAS 2 I get tired very quickly .33 -.62
FAS 4* I have enough energy for everyday life -.33
FAS 10* When I am doing something, I can concentrate quite well .83
FAS 7* I have problems thinking clearly -.54 -.56
DEFS: Dutch Exertion Fatigue Scale; FAS: Fatigue Assessment Scale.
*Excluded from further analyses.
D personality, and sleep problems. Together, these four variables explained 37
percent of the variance in general fatigue (see also Table 4).
As displayed in Table 5, the amount of shrinkage was relatively small.
This indicates that if the prediction equations were applied to other samples of
chronic heart failure patients, then on average the same proportion of variance
accounted for would be found. That is, the identified predictors of fatigue are
likely to be valid in CHF patients.
DISCUSSION
Fatigue is one of the most prevalent and aggravating symptoms in CHF,
and patients often rate fatigue as one of the most burdening consequences of
CHF [4]. However, little is known about factors that explain individual
differences in symptoms of fatigue [1,5,6]. Therefore, the primary aim of this
prospective study was to identify predictors of fatigue in chronic heart failure
patients. Exertion fatigue and general fatigue were identified as different
manifestations of fatigue. We found that exertion fatigue at 12-month follow-
up was predicted by decreased exercise capacity, dyspnoea, hypertension, and
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Female sex .23 .007
Low educational level .24 .006
Unemployment .23 .006
Exercise capacity -.44 <.001
NHYA class III/IV .30 <.001
Cardiac history .17 .04
Stroke .21 .013
Hypertension .23 .008
Beta blocker -.18 .04
Sleep problems .29 .001
Dyspnoea .33 <.001
Cardiac pain .42 <.001
Depressive symptoms .33 <.001
Type-D .20 .02
General fatigue
Exercise capacity -.24 .005
NHYA class III/IV .26 .002
COPD .20 .02
Hypertension .17 .05
Sleep problems .42 <.001
Dyspnoea .45 <.001
Cardiac pain .44 <.001
Depressive symptoms .42 <.001
Type-D .36 <.001
Table 4. Determinants of 12-month fatigue in stepwise
regression analyses
Factor B t-value p-value
Exertion fatigue
Exercise capacity -.35 -4.62 <.001
Hypertension .16 2.19 .03
Dyspnoea .24 3.16 .002
Depressive symptoms .16 2.01 .05
Full  model  information:  Rz=.32; F (4,131)=15.18; p<.001
General fatigue
Sleep problems .20 2.54 .01
Dyspnoea .24 3.00 .003
Depressive symptoms .27 3.67 <.001
Type-D .17 2.23 .03
Full  model  information:  Rz=.37; F (4,131)=19.22; p<.001
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Table 5. Cross-validity of regression models
Dependent variable 0    Rf    Shrinkage (%)
Exertion fatigue at follow-up   .32 .27 14.9
General fatigue at follow-up .37 .33 11.9
depressive symptoms. In contrast, general fatigue at 12-month follow-up was
predicted by dyspnoea, depressive symptoms, type-D personality, and sleep
problems. The finding that exertion fatigue and general fatigue were not
predicted by the same variables underlined that they represented different
dimensions of fatigue.
In accordance with the study of Friedman et al. [6], feelings of fatigue
were often accompanied by symptoms of dyspnoea. This was in line with
expectations since dyspnoea and fatigue are core symptoms of CHF [29].
Depressive symptoms were also associated with symptoms of fatigue, which
has previously been reported in studies of CHF [11,12], coronary [30], and
stroke patients [31]. Apart from dyspnoea and depressive symptoms, exercise
capacity and hypertension were important predictors of exertion fatigue. An
intervention study by Mayou et al. [32] also found an association between
fatigue and exercise capacity. Moreover, they found that increased exercise
capacity after the intervention was associated with decreased fatigue. From
previous studies, it is known that hypertension is often accompanied by
fatigue, especially in combination with certain kinds of medication [33,34].
Next to dyspnoea and depressive symptoms, sleep problems and type-
D personality emerged as predictors of general fatigue. Sleep problems and
fatigue were found to be associated in previous studies in CHF [35] and cancer
[36]. The effect of type-D on general fatigue might be explained by chronic
exposure to distress. Over time, the chronic nature of type-D may elicit a
discrepancy between resources and demands, which in turn may lead to
greater feelings of general fatigue as compared to non-type-D's. Moreover, the
association is in line with studies in coronary artery disease [13] and multiple
sclerosis [14]. The study by Friedman et al. [6] did not find a relationship
between fatigue and personality in CHF. However, they examined the effect of
optimism and pessimism, instead of type-D personality. Although
optimism/pessimism has been linked to negative affectivity [37], type-D
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personality does not only comprise negative affectivity, but also social
inhibition. This different finding could also be explained by the fact that the
present study used different questionnaires to assess fatigue, and by the fact
that the sample characteristics were not similar. Their subjects were more
likely to be female, to be older, to be unmarried, and to have a better left
ventricular ejection fraction as compared to our sample.
To our knowledge, this was the first study in chronic heart failure
patients that tried to identify predictors of both exertion and general fatigue.
Exertion fatigue was primarily predicted by physical characteristics, whereas
general fatigue was predicted by both physical and psychological
characteristics. This distinction might be important with respect to future
interventions aimed at the reduction of fatigue in CHF patients. After all, it is
unclear if and to what extent interventions should focus on either physical
symptoms, psychological symptoms, or both. Future studies should also aim to
reduce the effect of personality on general fatigue. Although changing
personality characteristics is very difficult, previous research has shown that
type-D's benefit from behavioural interventions in terms of mood and health
status [22]. Hence, targets of counselling could be improvement of self-
management abilities, consolidation of the social network, and improving
coping abilities. The results of this study are important, because use of this
knowledge by doctors and nurses may lead to a better understanding of the
clinical manifestations of fatigue in CHF, which in turn may lead to a more
effective treatment.
This study had a number of limitations. First, there may have been a
bias in the selection of patients. The cardiologist or heart failure nurses asked
patients to participate in the study, and this interaction pattern might have
influenced selection. Secondly, some variables were assessed by means of self-
report.
In summary, the present study showed that fatigue was predicted by
both clinical and psychological characteristics. Exertion fatigue at the 12-month
follow-up was predicted by dyspnoea, exercise capacity, hypertension, and
depressive symptoms, whereas general fatigue was predicted by dyspnoea,
depressive symptoms, type-D personality, and sleep problems.
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Although the present study revealed a number of predictors of fatigue
in CHF, a large portion of variance remained unexplained. Therefore, future
studies should focus on identifying these predictors. We suggest that more
physiological measures, which are known to be abnormal in CHF patients and
which are relevant with respect to symptoms of fatigue, for example measures
of abnormal muscle metabolism and enhanced ergo reflex response, should be
used [10]. Furthermore, future studies should examine the specific role of
exertion fatigue and general fatigue as predictors of poor prognosis in CHF.
Since some studies have already identified the importance of fatigue in terms
of CHF prognosis [1,2], it is also necessary to identify potential mechanisms
through which fatigue exerts its toxic effect. In this regard, it would be
interesting to investigate whether fatigue is related to poor self-management.
After all, it is well documented that poor self-management is associated with
adverse clinical outcome [38].
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Fatigue levels in stroke patients as compared to end-stage heart
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ABSTRACT
Objectives: The aim of the present study was to examine the assessment of
fatigue by the Fatigue Assessment Scale (FAS) in stroke patients and to
compare the levels of fatigue as reported by stroke patients, heart failure
patients, and healthy controls. Design: Cross-sectional analysis. Setting:
Stroke rehabilitation unit, heart failure outpatient clinic, general Dutch
population. Participants: Three different samples were included: 80 stroke
patients, 137 heart failure patients, and 160 healthy controls. Measurements:
Fatigue was measured by means of the FAS at baseline and at 2-month follow-
up. Depressive symptoms (BDI) were assessed at baseline. Results: The
internal consistency (a) of the FAS was .77 both at baseline, and at 2-month
follow-up. Test-retest reliability was .81 for a 2-month interval. Factor analysis
of the combined pool of FAS and BDI items revealed two distinct factors that
measure fatigue and depression as two separate constructs. Stroke patients
(15.3 f 7.6) and CHF patients (16.5 f 7.9) reported similar levels of fatigue
(p=.44). The level of fatigue in stroke and heart failure patients was
considerably higher as compared to healthy controls (9.2 f 5.6; p<.001).
Using the healthy controls as a reference group, multivariable logistic
regression revealed that stroke patients were at a 6-fold increased risk
(OR=6.18;95%CI 3.31-11.55, p<.001), and heart failure patients were at an
8-fold increased risk (OR=8.03;95%CI 4.63-13.94, p<.001), for having fatigue
symptoms. Conclusion: The FAS is an adequate measure of fatigue in stroke
patients. Levels of fatigue in stroke patients are similar to levels found in heart
failure patients, emphasizing its clinical significance in stroke.
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INTRODUCTION
Symptoms of fatigue are common among stroke patients. A substantial
proportion of stroke patients perceive fatigue as either their worst or one of
their worst symptoms.(1) Previous studies have reported that the prevalence of
post-stroke fatigue varies between 39-72%.(2) Nonetheless, fatigue has
received little attention in the stroke literature(3-5), which may partially be due
to its ambiguous nature.
A common way of assessing perceived fatigue is by means of
questionnaires. A recent study evaluated different fatigue scales that have
been used in stroke patients.(6) Based on their results, these authors
recommended the Fatigue Assessment Scale(7) (FAS) to measure fatigue after
stroke because the FAS had face validity, was feasible for most patients, had a
good test-retest reliability, and had high construct validity. Although promising,
these findings need to be replicated in a different sample of stroke patients.
The level of fatigue in stroke patients has previously been compared to
healthy controls(1) and to patients with multiple sclerosis(8). Since stroke
fundamentally is a vascular disease, it would be interesting to compare the
levels of fatigue to cardiac patients as well. Within the spectrum of
cardiovascular diseases, fatigue is most common in chronic heart failure(9)
(CHF) which could therefore serve as a useful reference group to compare the
levels of fatigue in stroke with.
The aim of the present study was 1) to examine the assessment of
fatigue by the FAS in stroke patients, and 2) to compare the levels of fatigue as
reported by stroke patients, CHF patients, and healthy controls.
METHODS
Participants
The first sample included 80 consecutive stroke patients visiting the
stroke rehabilitation unit of nursing home 'De Hazelaar', Tilburg, the
Netherlands. Their mean age was 74.1 years (* 6.6), 44 (55%) were male,
and 38 (47.5%) had a low educational level (i.e. primary school). Forty-one
(51.3%) had a right hemisphere stroke. Nineteen (23.7%) had a brainstem
lesion, 26 (32.5%) had a subcortical lesion, and 22 (27.5%) had a cortical
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lesion. No information on stroke location was available in 13 (16.3%) patients.
The stroke sample was severely disabled. The average score on the physical
dimension of the Stroke-Adapted Sickness Impact Profile (SA-SIP30)(10) was
72.8% (* 31.5) on the body care and movement subscale, 77.9% (* 26.0) on
the mobility subscale, 82.1% (* 29.0) on the ambulation subscale, and 36.3%
(* 30.6) on the alertness behavior subscale. Levels of disability were similar
across stroke locations. The mean time between stroke and study inclusion was
7.6 months (* 5.4). Stroke patients that suffered from reduced level of
consciousness, severe language deficits, multiple cognitive deficits reflecting
dementia syndrome, or severe emotional problems were excluded. In addition,
patients with other life-threatening diseases were excluded as well. Stroke
patients were interviewed with regard to fatigue and depressive symptoms at
baseline, and fatigue at 2-month follow-up.
The second sample comprised 137 end-stage CHF patients (NYHA-class
III/IV) visiting the heart failure outpatient clinic of the TweeSteden Hospital,
Tilburg, the Netherlands. Their mean age was 67.6 years (f 8.8), 98 (71.5%)
were male, and 48 (35%) had a low educational level. The mean left
ventricular ejection fraction was 28.9% (* 7.0). Inclusion criteria were systolic
heart failure, LVEF 540%, and sufficient understanding of the spoken and
written Dutch language. Patients with diastolic heart failure, age 280 years,
myocardial infarction in the month prior to inclusion, other life-threatening
diseases, or history of stroke were excluded. All patients completed a fatigue
questionnaire at baseline.
Finally, a third sample of 160 healthy controls from the general Dutch
population without a history of stroke or cardiovascular disease was used as a
reference group. Their mean age was 69.3 years (* 6.0), 74 (46.3%) were
male, and 34 (21.3%) had a low educational level. Research assistants were
responsible for distributing the fatigue questionnaire. They approached the
participants in person. Participants returned the questionnaires to the research
assistants. Data were managed anonymously.
The study protocol was approved by the medical ethics committee of
the respective institutions, and the study was conducted in accordance with the




Fatigue was measured by means of the FAS consisting of 10 items (e.g.
"I am bothered by fatigue" or "I get tired very quickly"). The response scale is
a 5-point scale (0=never to 4=always). Previous studies have shown that the
psychometric properties of the FAS were good in samples of the general
population(11), the working population(7), and the sarcoidosis population.(12)
A recent study in 55 stroke patients revealed that the FAS had face validity, it
was feasible for most patients, and it had good test-retest reliability and high
construct validity, but low internal consistency.(6)
Depressive symptoms
The BDI was used to examine divergent validity of the FAS. Symptoms
of depression were measured by using a shortened version of the Beck
Depression Inventory (BDI) consisting of 13 items.(13) The item on suicide
was excluded beforehand to limit the emotional burden. Each item is rated on a
0-3 scale. The BDI is a reliable and well-validated measure of depressive
symptomatology that is also suitable for stroke patients.(14)
Disability
The Stroke-Adapted Sickness Impact Profile (SA-SIP30) was used to
measure disability in the stroke sample.(10) Previous research has shown that
SA-SIP30 provides more clinical information than other frequently used
measures of disability.(15) Physical functioning was measured by the three
subscales body care and movement, mobility, and ambulation. Level of
cognitive impairment was measured by means of the alertness behavior
subscale. Each item is rated on a dichotomous scale (Yes/No). Subscale scores
are presented as a percentage of maximal dysfunction, ranging from 0% to
100%.
Statistical analyses
Cronbach's alpha coefficients were used to calculate the internal
consistency. Test-retest reliability was established using a Pearson correlation
between the FAS scores of the 80 patients who had completed the FAS twice.
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Construct validity (divergent) was examined in two ways. First, a principal
component analysis (PCA) with oblimin rotation was employed with the FAS
and the BDI in order to examine the divergent validity of the FAS. Oblimin
rotation was used because the extracted factors were expected to
correlate.(12) The scree plot criterion was used to determine the number of
factors. Secondly, Pearson correlations were calculated between the FAS scores
and the scores on the BDI.
Analysis of variance (ANOVA) was used to compare levels of fatigue
between stroke patients, CHF patients, and healthy controls. Tukey's test was
used for post-hoc analysis. In order to control for differences in age, sex, and
educational level between the two samples, analysis of covariance (ANCOVA)
was applied. Effect sizes (i.e. standardized differences between two mean
scores) were calculated by means of Cohen's d. By convention effect sizes are
defined as "small, d = .2," "medium, d = .5," and "large, d = .8". Logistic
regression was used to determine whether stroke patients were at increased
risk of having symptoms of fatigue as compared to healthy controls. All
analyses were performed using SPSS version 15.0.1.1.
RESULTS
Reliability and construct validity of the FAS in stroke patients
The internal consistency (a) of the FAS was .77 both at baseline, and at
2-month follow-up. Test-retest reliability was .81 for a 2-month interval. The
PCA on the combined pool of FAS and BDI items revealed two factors (Table 1).
Two FAS items loaded higher on the BDI component (FAS-8: no desire to do
things; FAS-6: problems starting), while the BDI item on fatigue loaded higher
on the FAS component. Overall, the FAS and the BDI represent two separate
scales that measure fatigue and depression as different concepts. However, the
component solution in Table 1 suggests that the FAS may not be a
unidimensional construct in stroke patients because 4 out of 10 items either
had low component loadings (FAS-3; FAS-7) or loaded on the BDI component
(FAS-8; FAS-6). Therefore, more research on the content validity of the FAS is
required in a larger sample of stroke patients. The association between the FAS
and the BDI was .44 (p<.001).
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Table 1. Component Loadings of the Fatigue and Depression Measures*
Item description Component 1 Component 2
BDI-2: despondent about future .72 .09
BDI-6: disappointed .69 -.01
BDI-3: failure .69 .11
BDI-4: not enjoying things .64 .29
BDI-1: sad .64 -.06
BDI-8: interest in others .59 -.10
BDI-10: appearance .57 -.01
FAS-8: no desire to do things .50 -.06
FAS-6: problems starting .46 -.19
BDI-11: activity .41 -.02
BDI-5: guilty .38 -.08
BDI-9: taking decisions .37 -.02
BDI-13: appetite .09 -.01
FAS-1:  bothered by fatigue -.13 -.87
FAS-2: tired quickly -.14 -.88
FAS-5: physically exhausted .05 -.84
BDI-12: fatigue .15 -.68
FAS-9: mentally exhausted .22 -.64
FAS-4: enough energy .15 -.58
FAS-10: concentrate well .16 -.42
FAS-3: don't do much -.05 -.26
FAS-7: problems thinking clearly .01 -.20
* loadings 2.35 are displayed in bold
Fatigue levels in stroke patients, CHF patients, and healthy controls
As displayed in Figure 1, stroke patients (15.3 f 7.6) and CHF patients
(16.5 f 7.9) reported similar levels of fatigue (p=.44). The level of fatigue was
considerably higher in stroke patients and CHF patients as compared to healthy
controls (9.2 f 5.6; p<.001). Controlling for age, sex, and educational level did
not alter these results. Moreover, computation of Cohen's d revealed that the
effect sizes for stroke and CHF were large as compared to the effect sizes for
gender and educational level (Figure 2). This result confirms the clinical
relevance of stroke as a determinant of fatigue.
Next, levels of fatigue were dichotomized using the highest quintile of
the healthy controls (FAS<12 = 0; FAS213 = 1). Accordingly, the prevalence
of increased fatigue was 61.3% (n=49) for stroke patients, and 67.3% (n=92)
for CHF patients. Using the healthy controls as a reference group, multivariable
logistic regression revealed that stroke patients were at a 6-fold increased risk
(OR=6.18; 95%CI 3.31-11.55, p<.001), and CHF patients were at an 8-fold
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increased risk (OR=8.03; 95%CI 4.63-13.94, p<.001) for having symptoms of
fatigue.
Figure 1. Mean level of fatigue stratified by medical condition
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p<.0001
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Disability as a predictor of fatigue in stroke patients
The four subscales of the SA-SIP30 were forced into a multivariable
model with fatigue as the dependent variable. Logistic regression revealed that
higher scores on the ambulation (OR=1.03; 95%CI 1.00-1.05, p=.03) and
alertness behavior (OR=1.04; 95%CI 1.02-1.07, p<.001) subscales were
associated with an increased risk of fatigue. The subscales body care and
movement, and mobility were not associated with fatigue in this sample of
stroke patients.
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Figure 2. Effect size estimates indicating the clinical significance of gender,
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DISCUSSION
This is the first study showing that levels of fatigue in stroke patients
were as high as the levels in CHF patients, who experience fatigue as one of
their main complaints. Levels in the stroke population were also significantly
higher than levels in the normal population. Moreover, both stroke and CHF
had a large effect on fatigue. These findings clearly emphasize the importance
of fatigue in stroke patients. To measure fatigue, the FAS may be well
applicable in stroke patients, since the FAS had good internal consistency as
well as test-retest reliability in our stroke population. Moreover, the divergent
validity of the FAS was good, since the FAS was found to measure fatigue and
not depression. Only the unidimensionality of the FAS was questioned in our
data. Disability levels partly explained fatigue in stroke patients.
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Fatigue is a common complaint after stroke, although research has
neglected this issue for years.(1-5) In our study, nearly two third of the
patients experienced increased levels of fatigue 7.5 months after stroke. This is
in line with previous studies, which reported a prevalence of fatigue between
39 and 72%.(2) Together with the notion that levels of fatigue in stroke
patients were equal to the levels in CHF patients and both stroke and CHF had
a large effect on fatigue, the issue of fatigue cannot be ignored in the stroke
population. In addition, the impact of fatigue on quality of life and prognosis
needs to be determined. Previous studies have shown an association between
fatigue and increased dependency in activities of daily living(5) and decreased
health related quality of life(16). Only one study researched the relationship
between fatigue and mortality and reported a significant association(5).
Recent research has recommended the FAS to measure fatigue in
stroke patients.(6) These authors reported lower internal consistency, but
otherwise good reliability and validity of the FAS. Our results are largely in line,
with good validity and reliability, including the internal consistency. However,
the unidimensionality of the FAS, which has been described in other
populations(7,11,12), was not supported in our stroke population, since 4 out
of 10 items had low loadings on the FAS-factor. Hence, fatigue in the stroke
population may be different from fatigue in other populations. In addition,
Mead et al(6) reported that the FAS measures different facets of fatigue.
Clearly, more research on the internal consistency, as well as the content
validity of the FAS is warranted, but also the use of larger samples, because
this study was based on 80 patients and the Mead et al(6) study on 55
patients.
Considering that levels of fatigue are equally high in stroke and CHF
patients and effect sizes were large, several implications for clinical practice
emerged. First, recognition of fatigue in stroke patients is important. We and
others(6) advocate the FAS, since it has sound psychometric properties and
contains only 10 items. Second, treatment of fatigue is important, but only one
clinical trial focused on the treatment of fatigue, showing that fluoxetine did not
improve fatigue(17). In other studies, several treatments were proposed,
including evaluation of current medications, screening for depression,
minimizing sleep disturbances, exercise programs, and patient education(18).
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More research is needed on the treatment of fatigue as well as on the efficacy
of the treatment.
A limitation of this study is the relatively small sample size, by which
we were unable to draw definitive conclusions concerning the content validity
of the FAS. Also, the generalizability of the results to the stroke population may
be limited due to the exclusion of patients, suffering among others from a
reduced level of consciousness. Despite these limitations, results of this study
are clear, indicating that levels of fatigue in stroke patients were as high as the
levels in CHF patients, and that both the effect of stroke and CHF on fatigue
was large.
In conclusion, levels of fatigue in stroke patients are equal to the levels
of fatigue in CHF patients, who experience fatigue as one of their main
complaints. Moreover, both stroke and CHF had a large effect on fatigue,
emphasizing its clinical importance in stroke patients. The FAS is an adequate
measure of fatigue in stroke patients, but the content validity of the FAS in
these patients needs to be examined in future studies.
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Patient-rated changes in fatigue over a 12-month period
predict poor outcome in chronic heart failure
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ABSTRACT
Background and objectives: Little is known about factors that are associated
with changes in fatigue in chronic heart failure (CHF). Moreover, it is unclear
whether these changes have prognostic impact. The aim of this study was to
examine these issues. Methods: 387 CHF patients were assessed twice (at
baseline and at 12-month follow-up) for exertion and general fatigue.
Regression models were developed to assess whether baseline characteristics
predicted changes in fatigue, and to assess the effect of changes in fatigue on
cardiac events occurring beyond 12-month follow-up. Results: An increase in
exertion fatigue over a 12-month period was predicted by higher left
ventricular ejection fraction (p=.02) and cognitive-affective depressive
symptoms (p=.03) at baseline, and not having a biventricular pacemaker
shortly after baseline (p=.02), whereas an increase in general fatigue was only
predicted by cognitive-affective depressive symptoms (p=.002). 143 patients
(37%) experienced an event (readmitted=117; death=26). An increase in
exertion fatigue was associated with a near 2-fold increased risk of adverse
events beyond 12-month follow-up (HR=1.78; 95%CI 1.18-2.68, p=.006),
while controlling for standard cardiac risk factors. Conclusions: Baseline
clinical and psychosocial factors predicted changes in fatigue. Increased




Fatigue is commonly reported by chronically ill patients [1-3]. In
chronic heart failure (CHF), fatigue is one of the most prevalent and distressing
symptoms, that is also associated with disease progression [4-7].
Nevertheless, research concerning the clinical relevance of self-reported fatigue
in CHF may be underreported in the cardiovascular literature, which may
partially be due its ambiguous nature.
Explaining fatigue in CHF has proven to be difficult [6,8]. Previous
studies have shown that left ventricular function measures relate poorly to
fatigue [9,10]. Nevertheless, fatigue has been explained by impaired skeletal
muscle blood supply as a result of reduced cardiac output [11]. Recently, it has
been suggested that chronic, low grade haemodynamic stress as seen in CHF
may lead to dominance of catabolic processes. This in turn leads to skeletal
myopathy, causing the sensation of fatigue [11,12]. However, it remains
unclear to what extent these factors may fully explain individual differences in
fatigue.
Previous studies have demonstrated patients' self-assessment of CHF
symptoms to be independently associated with poor prognosis [13,14]. In
addition, it was shown that self-assessed symptoms and New York Heart
Association (NYHA) classification were not coherent [13], indicating that there
was little agreement between the patient and physician rated CHF symptoms.
Self-assessed fatigue may therefore provide useful additional information about
the patients' clinical and prognostic status.
The dynamic nature of symptoms in general, and fatigue in particular
makes it necessary to examine these symptoms prospectively over time.
Efforts should be made to gain knowledge about subgroups of CHF patients
that are at increased risk to develop worse fatigue status over time, thereby
providing an opportunity for risk stratification and prevention. Moreover, the
prognostic impact of changes in self-reported fatigue should be examined as
well.
The aims of this study were: (1) to determine clinical, demographic,
and psychological predictors of changes in fatigue over a 12-month period, and
(2) to examine whether these changes in fatigue were predictive of adverse




The sample comprised 387 CHF patients (70.3% males; mean (SD) age
= 66.4 (10.7) years; NYHA class III/IV = 42.9%) visiting the heart failure
Outpatient clinic of the TweeSteden Hospital, Tilburg, the Netherlands (see
Table 1 for descriptives). Inclusion criteria were defined as systolic heart
failure, LVEF540%, and sufficient understanding of spoken and written Dutch
language. Exclusion criteria were defined as diastolic heart failure, age 2 80
years, myocardial infarction in the month prior to inclusion, and other life-
threatening diseases.
Patients completed a questionnaire at baseline and at twelve-month
follow-up. Information about cardiac readmission or death was collected
beyond 12-month follow-up. The overall design of our study is shown in Figure
1. The hospital's medical ethics committee approved the study protocol, and
the study was carried out according to the Helsinki Declaration. All patients
provided written informed consent. Of the original 419 patients, 32 were
excluded from the final analyses because they died between baseline and 12-
month follow-up, hence, changes in fatigue could not be assessed.
Figure 1. Design of the study
Assessment of fatigue Assessment of first
change between cardiovascular readmission
baseline and 12-month or death beyond 12-month
follow-up follow-up
14   .1 .1 = 24 months
Baseline 12 months (mean follow-up)
Changes in fatigue
Previous research has suggested to differentiate between exertion and
general fatigue; the former refers to fatigue directly related to the performing
of activities in daily living [15], and the latter refers to an overwhelming,
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sustained sense of exhaustion that does not necessarily have a relationship
with exertion [16]. The Dutch Exertion Fatigue Scale (DEFS) assesses exertion
fatigue by means of 9 items [15]. Items are answered with five response
alternatives ranging from 0 (no) to 4 (yes). Cronbach's alpha was good in the
present study (a=.91). The Fatigue Assessment Scale (FAS) was used to
assess general fatigue [17]. This questionnaire consists of 10 items, which are
answered on a 5-point Likert scale, ranging from 1 (never) to 5 (always). In
the present study, the reliability of this instrument was high (a=.90).
Changes in exertion and general fatigue were calculated by means of
residualized change scores (dexertion fatigueres, Ageneral fatigueres)· These
change measures reflect the degree to which an individual increased or
decreased more than would be expected given his or her initial status.
Residualized change scores are preferable to simple change scores because
they eliminate auto correlated error and regression to the mean effects [18].
Clinical events beyond 12-month follow-up
Patients' hospital medical records were used to assess whether patients
had been readmitted for cardiovascular causes since 12-month follow-up. The
same procedure was followed to assess mortality. Accordingly, the combined
clinical endpoint was defined as cardiac hospital readmission or death. The
mean duration of follow-up counting from 12 months after baseline was 782
days (range 1-1798 days).
Clinical correlates
Clinical variables included LVEF, NYHA class, aetiology of CHF, cardiac
history, biventricular pacemaker status, smoking status, body mass index
(BMI), six minute walking test, physical inactivity, co morbidities, and
medication. Information on clinical variables was obtained from the patients'
medical records and from the treating cardiologist. Socio-demographic
information included sex, age, marital status, and educational level.
Symptoms of dyspnoea
Since dyspnoea is one of the core symptoms of CHF, it was included as
a potential predictor of changes in fatigue. Symptoms of dyspnoea were
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measured by a subscale of the Health Complaint Scale [19]. Items are
answered on a 5-point Likert scale, ranging from 0 (not at all) to 4
(extremely).
Symptoms of depression
Symptoms of depression were assessed by means of the Beck
Depression Inventory (BDI) [20]. Each item is rated on a 0-3 scale. The BDI is
a reliable and well-validated measure of depressive symptomatology [21,22],
and is the most widely used self-report measure of depression. Since the
somatic items of the BDI may be confounded by fatigue, only the cognitive-
affective subscale was used [23].
Type-D personality
Personality was used as a potential determinant of changes in fatigue
as well. Type D personality was assessed by means of the 14-item Type D
Scale (DS14), which comprises two subscales, Negative Affectivity and Social
Inhibition [24]. A standardized cut-off score 210 on both subscales classifies
individuals as having a Type D personality. Both scales have good internal
reliability (a=.88 and .86, respectively), and are stable over time [24,25].
Statistical analyses
Prior to statistical analyses, educational level, marital status, NYHA-
class, aetiology of heart failure, co-morbidities, and cardiac history were
recoded into dichotomous variables. At 12-month follow-up, 19.4% of the DEFS
scores and 19.1% of the FAS scores were missing. Simply discarding those
patients wastes potential information and could bias results. Therefore, SAS
procedure MI (multiple imputation) was used to create ten data sets to
estimate values for missing data. After ordinary analysis, SAS procedure
MIANALYZE was used to combine the results of the ten datasets [26,27].
SAS procedure REG was used to determine predictors of changes in
fatigue. All baseline variables were forced into a multivariable model predicting
respectively changes in exertion fatigue and changes in general fatigue. Cox
proportional hazards regression, by means of the SAS procedure PHREG, was
used to assess whether changes in fatigue predicted the combined end-point of
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cardiovascular readmission or death beyond the 12 month follow-up. In
multivariable analysis, we included standard cardiac risk factors (age, gender,
smoking, BMI, physical inactivity, hypertension, hypercholesterolemia, and
diabetes), measures of disease severity (LVEF, NYHA-class), and variables that
predicted changes in fatigue.
RESULTS
Baseline characteristics
Of all included patients, 32 died between baseline and 12 month follow-
up and were excluded from further analysis. Patients who completed the study
differed systematically from patients who died within 12 months after baseline.
Patients who died were more likely to be older (t=2.76, df=419; p=.006), male
(x2=4.31, df=1; p=.04), physically inactive (x2=4.06, df=1; p=.04), and were
more likely to be in NYHA-class III/IV (x2=6.02, df=1; p=.01). In addition,
they had lower ejection fraction (t= -2.83, df=404; p=.005), and lower
exercise capacity (t= -4.11, df=413; p<.001). Baseline levels of both exertion
(t=3.18, df=415; p=.002) and general fatigue (t=2.14, df=413; p=.03) were
significantly higher in patients that died between baseline and 12 months
follow-up as compared to patients who completed the study. Baseline
characteristics of the sample included in final analyses (n=387) are displayed
in Table 1.
Predictors of changes in fatigue
Multiple regression analysis revealed that changes in exertion fatigue
over a 12-month period were predicted by LVEF, implementation of a BVP,
beta-blockers, and cognitive-affective depressive symptoms. Patients having a
higher LVEF, having more cognitive-affective depressive symptoms, not having
a BVP, and not using beta-blockers were more likely to have an increase in
exertion fatigue at 12-month follow-up. Changes in general fatigue were only
predicted by cognitive-affective depressive symptoms. Patient with higher
levels of depressive symptoms showed a greater increase in general fatigue at
12-month follow-up as compared to patients with lower levels of depressive
symptoms (Table 2).
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Table 1. Baseline characteristics
Age (SD) 66.4 (10.7)
Male gender, % (n) 70.3 (272)
Low educational level, % (n) 33.3 (129)
Having a partner, % (n) 70.8 (274)
Smoking, % (n) 23.0 (89)
Body Mass Index (SD) 28.6 (12.0)
Physical inactivity, % (n) 44.2 (171)
LVEF (SD) 30.7 (6.8)
NYHA-class III/IV, % (n) 42.9 (166)
Ischemic aetiology, % (n) 54.5 (211)
Hypertension, % (n) 39.8 (154)
Hypercholesterolemia, % (n) 47.5 (184)
Diabetes, % (n) 23.8 (92)
Co-morbidity, % (n)* 38.0 (147)
Implementation of BVP, % (n)t 9.3 (36)
Cardiac history, % (n)* 57.4 (222)
ACE-inhibitors, % (n) 73.1 (283)
Diuretics, % (n) 72.6 (281)
Beta-blockers, % (n) 66.9 (259)
Statins, % (n) 49.9 (193)
Aspirin, % (n) 42.9 (166)
Psychotropic medication, % (n) 13.2 (51)
Six minute walking test (SD) 276.3 (159.6)
Symptoms of dyspnoea (SD) 2.4 (2.2)
Cognitive-affective depressive symptoms (SD) 1.3 (2.8)
Type-D personality, % (n) 19.6 (76)
* Stroke, COPD, peripheral arterial disease, liver disease, renal insufficiency
t Implementation of a biventricular pacemaker shortly after baseline
* History of MI, CABG, PCI




Implementation of BVP -0.14 .03
Beta-blocker -0.11 .05
Cognitive-affective depressive symptoms 0.17 .02
General fatigue
Implementation of BVP -0.12 .09
Statins -0.13 .07
Cognitive-affective depressive symptoms 0.20 .002
*Only variables with p<.10 are reported
Note: BVP: biventricular pacemaker, LVEF: left ventricular ejection fraction
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Changes in fatigue and hospital readmission/death
As indicated before, the composite endpoint was defined as cardiac
hospital readmission or death that occurred beyond 12-month follow-up. The
mean duration of follow-up counting from 12 months after baseline was 782
days (range 1-1798 days). Over the period of follow-up, 143 patients (37%)
experienced an event (readmitted=117; death=26).
In univariable analysis, both an increase in general fatigue (HR=1.04;
95%CI 1.00-1.07, p=.03) and exertion fatigue (HR=1.04; 95%CI 1.01-1.07,
p=.005) were associated with an increased risk of cardiovascular readmission
or death. In multivariable analysis, we controlled for the variables listed in
Table 3. Accordingly, increased exertion fatigue was an independent predictor
of cardiovascular readmission or death (HR=1.04; 95%CI 1.00-1.07, p=.03).
Smoking (HR=1.58; 95%CI 1.08-2.32, p=.02), BMI (HR=1.01; 95%CI 1.00-
1.02, p=.04), and diabetes (HR=1.61; 95%CI 1.09-2.36, p=.02) also predicted
cardiovascular readmission or death. General fatigue did not predict clinical
events in multivariable analysis.
Table 3. Multivariable predictors of cardiovascular readmission or death
Variable HR 95%CI p-value
Age (SD) 1.00 0.98-1.01 .72
Male gender 1.46 0.97-2.21 .07
Hypertension 0.82 0.58-1.17 .28
Hypercholesterolemia 0.99 0.68-1.45 .97
Smoking 1.58 1.08-2.32 .02
Body Mass Index 1.01 1.00-1.02 .04
Physical inactivity 1.16 0.82-1.65 .40
Diabetes 1.61 1.09-2.36 .02
LVEF (SD) 0.99 0.97-1.02 .49
NYHA-class III/IV 1.37 0.95-1.96 .09
Statins 1.17 0.80-1.73 .42
Beta-blocker 0.92 0.64-1.33 .67
Implementation of BVP 0.62 0.30-1.28 .19
Cognitive-affective depressive symptoms 1.00 0.94-1.06 .94
AGeneral fatigueres 1.01 0.97-1.05 .59
AExertion fatigueres 1.04 1.00-1.07 .03
Note: BVP: biventricular pacemaker, LVEF: left ventricular ejection fraction
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Next, dexertion fatigueres was dichotomized using the highest quintile
(Aexertion fatigueres<5 = 0; Aexertion fatigueres 25 = 1). Accordingly, the
event rate was 34% (n=104) in the non-increased exertion fatigue group, and
46% (n=39) in the increased exertion fatigue group. The Kaplan-Meier curve in
Figure 2 shows that patients in the increased exertion fatigue group were more
likely to experience an event as compared to patients in the non-increased
exertion fatigue group (p=.01). Multivariable analysis revealed that patients in
the increased exertion fatigue group had a near 2-fold increased risk of
experiencing an adverse event (HR=1.78; 95%CI 1.18-2.68, p=.006).
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To the best of our knowledge, this is the first study to examine the
predictors of changes in fatigue over time in CHF patients and to examine the
prognostic impact of these changes in fatigue in CHF. An increase in exertion
fatigue over a 12-month period was predicted by higher LVEF and cognitive-
affective depressive symptoms at baseline, and by not having implementation
of a BVP shortly after baseline. An increase in general fatigue was only
predicted by cognitive-affective depressive symptoms.
Increased exertion fatigue at 12 months follow-up were independently
associated with an increased risk of cardiovascular readmission or death
beyond 12 months follow-up, whereas an increase in general fatigue was only
associated with adverse outcome in univariable analysis. These results are in
line with studies that show that fatigue in CHF [7,13,14], and increased fatigue
in coronary patients [28] are associated with adverse outcomes.
Fatigue is considered to be one of the most important factors in
affecting the patients' quality of life, and there is growing need for adequate
clinical management of fatigue [29,30]. Nonetheless, little is known about why
patients experience fatigue [31], and explaining individual differences in fatigue
has proven to be difficult [6]. The current study identified factors that
contribute to change in fatigue over time in CHF patients. In accordance with
previous work [32], implementation of a BVP was associated with a decrease in
exertion fatigue. Changes in both exertion fatigue and general fatigue were
predicted by cognitive-affective depressive symptoms at baseline. This result
extends our previous findings [8], and lends further support to the possible role
of depression in the perception and reporting of disease specific symptoms in
CHF [8]. The association between higher LVEF and increased exertion fatigue
was counterintuitive but it could be that better status on both LVEF and
exertion fatigue at baseline is more likely to deteriorate than if either or both
are already significantly impaired .
The current study emphasizes the importance of recognizing changes in
fatigue in clinical practice. Recognition of these changes allows health care
professionals to act on this, for example by offering exercise training. The
importance of exercise training was recently reviewed in a meta-analysis by
Puetz et al [33], in which they showed that cardiac rehabilitation exercise
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programs have considerable effects on levels of energy and fatigue. However,
it remains unclear whether improvement after therapy is associated with
improved prognosis. Future studies should address this issue.
In addition, the mechanisms through which fatigue exert its negative
effects are unclear. We hypothesize that mechanisms are different for exertion
fatigue and general fatigue. Exertion fatigue may primary reflect the direct
physical consequences of the disease itself, and an increase of exertion fatigue
may therefore reflect worsening of CHF. Future studies should assess
physiological measures that are known to be abnormal in CHF patients and that
are relevant with respect to fatigue, for example measures of abnormal muscle
metabolism and an enhanced ergo reflex response [11,12]. Future studies
should measure in parallel changes in exertion fatigue and such physiological
parameters. On the other hand, general fatigue may reflect the more
psychological consequences of CHF and may, to some extent, be on par with
mental fatigue. A hint towards this association was given by the fact that the
increase in general fatigue was predicted only by cognitive-affective depressive
symptoms. Increased general fatigue may therefore have impact on the
patients' ability for self-care, which has been associated with poor prognosis in
CHF [34].
There is also some evidence that vital exhaustion, a concept related to
general fatigue, is associated with increased levels of inflammatory markers in
patients with coronary heart disease [35,36]. These cytokines have been
associated with adverse outcomes in CHF [37-39]. Indeed, one important sign
of peripheral inflammatory signals is fatigue and behavioural withdrawal [40],
as part of the sickness response. Further research into the mechanisms
responsible for the link between fatigue and CHF prognosis is warranted in
order to optimize treatment strategies. Given the failure of anti-TNF medication
to improve prognosis in CHF [41], and if increases in fatigue are found to be
related to proinflammatory cytokines, such interventions may be more effective
if provided specifically to patients with worse fatigue.
This study had a number of limitations. First, there may have been a
bias in the selection of patients. The cardiologist or heart failure nurses asked
patients to participate in the study, and this interaction pattern might have
influenced selection. Second, we used combined endpoints in order to increase
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the number of clinical events, and did not use mortality as a separate endpoint.
Factors predicting readmission may differ from those predicting death. Third,
we did not have data available on changes in variables other than fatigue. For
future studies, it would be interesting to determine whether changes in cardiac
function, renal function, 6-minute walk test or peak oxygen consumption are
related to changes in fatigue. Fourth, we did not have information on diagnosis
of major depression. Nevertheless, the strengths of the current study were the
repeated assessment of fatigue over time, and the prospective design
examining the impact of these changes in fatigue on prognosis. Finally, we
used reliable and valid measures of both exertion and general fatigue.
In summary, changes in fatigue were related to clinical and
psychosocial factors, and increased exertion fatigue independently predicted an
increased risk of cardiac readmission or death. The current study contributes to
the understanding of fatigue in CHF, and reveals that changes in fatigue are of
clinical and prognostic importance. Taking symptom changes into account, in
addition to their biomedical and psychosocial predictors, may lead to improved
risk stratification and clinical management in this high-risk patient group.
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ABSTRACT
Aim: Fatigue is a poorly understood symptom in chronic heart failure (CHF).
We examined the different trajectories of fatigue over a 12-month period and
their impact on mortality in CHF. Methods: Consecutive CHF patients (N=310)
were assessed at baseline, 2- and, 12-month follow-up for symptoms of
exertion and general fatigue. Latent growth mixture modelling was used to
examine the course of fatigue over time. The endpoint was mortality following
the 12-month assessment of fatigue. Results: Over the initial 12-month
follow-up, 6 distinct trajectories for exertion fatigue and 4 distinct trajectories
for general fatigue were identified. Age, sex, exercise capacity, physical
inactivity, somatic comorbidities, and psychotropics use were significant
predictors of these trajectories. Beyond the 12-month follow-up (mean follow-
up period 693 days), 50 patients (17%) had died. Compared to the reference
group, both severe exertion fatigue (HR=2.59; 95%CI 1.09-6.16, p=.03) and
severe general fatigue (HR=3.20; 95%CI 1.62-6.31, p=.001) independently
predicted an increased mortality rate (29% vs. 19% and 28% vs. 14%,
respectively). Low exertion fatigue was associated with a decreased mortality
rate (3% vs. 19%; HR=0.12; 95%CI 0.02-0.93, p=.04). Conclusions: Fatigue
trajectories varied across CHF patients, and had a differential effect on
mortality. Persistent severe fatigue was a predictor of poor prognosis. These
results may help identify distinct groups of CHF patients with potentially
differential risks of adverse health outcomes.
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INTRODUCTION
Fatigue is considered one of the key symptoms in chronic heart failure
(CHF), as symptoms of fatigue to a large extent determine the patient's quality
of life (1). Moreover, it has also been suggested that symptoms of fatigue may
be associated with poor cardiovascular outcomes in CHF (2-5).
Research on fatigue in CHF has primarily focused on its
pathophysiological underpinnings (6,7), and its determinants (3,8-13). It has
been suggested that chronic, low grade haemodynamic stress as seen in CHF
may lead to dominance of catabolic processes, which in turn leads to skeletal
myopathy, causing the sensation of fatigue (6,7). Other studies have identified
symptoms of dyspnoea, symptoms of depression, and personality factors as
important determinants of fatigue in CHF (11-14). Nonetheless, fatigue is still
beyond complete comprehension, and it is unlikely that the factors mentioned
above fully explain individual differences in fatigue.
Fatigue is highly prevalent among CHF patients, and progression of CHF
is on par with an increase in symptoms of fatigue (1,3,4,11). However, the
evolution of fatigue over time is not the same for all patients with CHF. It may
be important to distinguish distinct developmental trajectories of fatigue in
CHF, as knowledge of fatigue trajectories, their clinical and psychological
determinants, and their prognostic impact allow for the identification of high-
risk CHF patients who may need additional clinical care above and beyond the
standard medical management of the disease.
Since the course of fatigue has not been studied in CHF patients, the
currents study's objective was to examine 1) the course and predictors of
symptoms of fatigue in CHF during a 12-month period, and 2) their prognostic
impact beyond the 12-months follow-up.
METHODS
Patients
This study included 310 CHF patients with systolic heart failure and a
left ventricular ejection fraction (LVEF) 540%, visiting the heart failure
outpatient clinic of the TweeSteden hospital, Tilburg, the Netherlands. Of the
378 patients that were initially included, 44 patients died during the first year
of the study, and 24 patients had missing questionnaire data on 2 or more
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measurement points, leaving 310 patients for the present study. Patients with
diastolic heart failure, age 280 years, myocardial infarction in the month prior
to inclusion, other life-threatening diseases, and no or insufficient
understanding of spoken and written Dutch language were excluded on
beforehand.
Patients completed a questionnaire at baseline, 2-month follow-up, and
12-month follow-up. The study protocol was approved by the local medical
ethics committee in Tilburg, the Netherlands. The study was conducted
conform to the Helsinki Declaration and every patient provided written
informed consent.
Symptoms of fatigue
Previous research suggests to differentiate between exertion and
general fatigue (5,12),the former referring to fatigue directly related to the
performing of activities in daily living, and the latter to an overwhelming,
sustained sense of exhaustion that does not necessarily have a relationship
with exertion. The Dutch Exertion Fatigue Scale (DEFS) assesses exertion
fatigue by means of 9 items (15). Items are answered with five response
alternatives ranging from 0 (no) to 4 (yes). Chronbach's alpha is high (a=91).
The Fatigue Assessment Scale (FAS) was used to assess symptoms of general
fatigue (16). This questionnaire consists of 10 items, which are answered on a
5-point Likert scale, ranging from 0 (never) to 4 (always). The reliability of this
instrument is high (a=.90).
Demographic and clinical variables
Demographic variables included sex, age, marital status, and
educational level. Clinical variables comprised LVEF, NYHA functional class, CHF
etiology, diabetes mellitus, hypertension, hypercholesterolemia, co-morbidities
(stroke, chronic obstructive pulmonary disease, peripheral arterial disease,
renal insufficiency), cardiac history (MI, percutaneous coronary intervention
(PCI), coronary artery bypass graft (CABG)), smoking status, physical
inactivity, body mass index (BMI), cardiac medication, and psychotropic
medication. Exercise capacity was measured by means of the six-minute
walking test (SMWT - walking small circuits of 52 meters), which was carried
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out within the hospital as part of this study. Patients were instructed to walk at
a normal pace, and to continue walking until they were told to stop or until
they experienced too many adverse symptoms. Patients were not encouraged
to walk as far as possible because the test was meant to reflect daily life
exercise capacity. Information on clinical variables was obtained from the
medical records and from the treating cardiologist or heart failure nurse.
Mortality beyond 12-month follow-up
Patients' hospital medical records were used to assess mortality since
12-month follow-up. The mean duration of follow-up counting from 12 months
after baseline was 693 days (range 74 -1516 days).
Statistical analyses
Prior to statistical analyses, age (<60 yrs vs. 260 yrs), educational
level (low vs. higher), marital status (partner vs. no partner), LVEF (<30% vs.
230%), NYHA functional class (I/II vs. III/IV), CHF etiology (ischemic vs. non-
ischemic), co-morbidities (present vs. not present), cardiac history (present vs.
not present), and exercise capacity (<300 meters vs. 2300 meters) were
recoded into dichotomous variables.
Latent class regression analysis was employed to examine trajectories
of fatigue symptoms in CHF patients over a 12-month period (17). A finite
mixture model was fit to identify classes of individuals following similar
patterns of behavior over time. The model assumes unobserved latent
variables to explain the associations among observed scores, and can be seen
as a categorical equivalent of factor analysis. One of the problems with fitting
these types of latent class models is that the categorization into classes is
dominated by the overall symptom levels which makes it less likely that the
model picks up symptom changes. A way to overcome this problem is the
inclusion of a random intercept (18).
To determine the optimal number of trajectories, the Aiken Information
Criterion 3 (AIC3) was used, with a higher AIC3 indicating a better fit.
However, a difference of less than 3 will favor the least complex model. Recent
studies have shown that AIC3 is a better criterion than BIC and AIC in
determining the number of latent classes in LC models (19,20).
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For comparison between classes we used the Chi-square test for
discrete variables. Adjusted Standardized Residuals (ASRs) were used to
identify groups responsible for significant differences. A residual greater than
2.0 was taken to indicate a significantly higher frequency, and a residual less
than -2.0 was considered to indicate a significantly lower frequency, than
expected if the independence hypothesis was true (21). Variables that were
significant in the univariate Chi-square analyses were entered into a
multivariate multinomial logistic regression model to assess whether
demographic, medical, and psychological variables were predictors of
trajectories of symptoms of fatigue.
Cox proportional hazards regression was used to assess whether
fatigue trajectories predicted mortality beyond 12-month follow-up. In
multivariate Cox regression, we included age, gender, BMI, physical inactivity,
diabetes mellitus, and a measure of disease severity (LVEF) because of their
relation with cardiovascular prognosis and fatigue. The LC cluster analysis was
performed with the LCA program Latent GOLD (17). All other data were
analyzed using SPSS 15.0.1 for Windows. A similar approach has previously
been used in MI- (22), PCI- (23), and PAD patients (14).
RESULTS
Trajectories of exertion fatigue
Figure 1 displays the six distinct developmental trajectories for exertion
fatigue. The AIC3 improved from one class of exertion fatigue (AIC3 = -6353)
to six classes of exertion fatigue (AIC3 = -5899), whereas a relative decline
was observed in the seven class model (AIC3 = -5903). Compared to the five
class model (AIC3 = -5915), the six class model achieved a significant
improvement in fit. The six class model was therefore adopted for further
analysis.
The first class (12.6% of the sample) was classified as the low exertion
fatigue group and was stable of time (intercept=1.69, p<.001; slope= -0.0054,
p=.76). The level of exertion fatigue in the second class (21.9%) was slightly
higher than in the first class and stable over time (intercept=5.91 , p<.001;
slope= -0.011, p=.72), and was therefore classified as the mild exertion
fatigue group. Class three (31.0%) had a moderate offset with an observed
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Figure 1. Observed trajectories of exertion fatigue
--11--Severe exertion fatigue (11.3%)
- -8- - -Increased exertion fatigue with moderate offset (16.8%)
- - -0- - - Increased exertion fatigue with mild offset (6.5%)
- - - Reference group (31.0%)
-Mild exertion fatigue (21.9%)
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mean DEFS-score at baseline of 19.94 (95%CI: 18.61-21.27) but showed a
significant decrease of exertion fatigue over time (intercept=18.87, p<.001;
slope= -0.28, p=.004). Since the third class comprises the largest group of
patients it was conceptualized as the reference group in the present study. The
fourth class (6.5%) was described as increasingly fatigued with a mild offset
(observed mean baseline DEFS-score = 8.40,95%CI: 6.50-10.30; model
intercept=8.07, p<.001; slope=0.74, p<.001). Class five (16.8%) had an
increase of exertion fatigue and a moderate offset (observed mean baseline
DEFS-score = 16.33, 95%CI: 14.06-18.60; model intercept=17.03, p<.001;
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slope=0.31, p=.05). Finally, the sixth class (11.3%) was classified as severely
fatigued across all assessment points (intercept=31.45, p<.001; slope= -
0.006, p=.92).
Trajectories of general fatigue
The levels of general fatigue were relatively stable over time for most
patients (Figure 2). The AIC3 improved from one class of general fatigue (AIC3
= -5863) to four classes of general fatigue (AIC3 = -5741), whereas a relative
decline was observed in the five-class model (AIC3 = -5749). Compared to the
three-class model (AIC3 = -5745), the four-class model achieved a significant
improvement in fit. A four class model for general fatigue was therefore
adopted for further analysis.
The first class (29.4% of the sample) was classified as the low general
fatigue group and was stable over time (intercept=8.55, p<.001; slope= -
0.095, p=.06). The second class (45.5%) had fairly stable moderate levels of
fatigue, and was conceptualized as the reference group since this class
comprises the largest group of patients (intercept=15.10 , p<.001; slope= -
0.090, p=.04). The third class (6.8%) was described as increasingly fatigued
with a mild offset (observed mean baseline FAS-score = 12.05, 95%CI: 9.84-
14.26; model intercept=13.13, p<.001; slope=0.71, p<.001). Finally, the
fourth class (18.4%) was classified as severely fatigued across all assessment
points (intercept=22.50, p<.001; slope= -0.10, p=.06).
Baseline characteristics stratified by fatigue class
There were a number of differences in demographic, clinical, and
psychological characteristics at baseline as a function of exertion fatigue class
(Table 1) and general fatigue class (Table 2). Departure from independence
was most pronounced in the extreme exertion fatigue groups, (Table 1;
numbers in bold). Patients in the low exertion fatigue group were younger
(ASR= -3.6), and less likely to be obese (ASR= -2.2), diabetic (ASR= -2.9),
low on exercise capacity (ASR= -4.2), in a higher NYHA-class (ASR= -3.3), or
to be on diuretics (ASR= -2.5). Patients in the severe exertion fatigue group
were more likely to be female (ASR=2.9), obese (ASR=2.0), physically inactive
(ASR=5.0), to have comorbidities (ASR=2.1), low exercise capacity (ASR=6.3),
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Figure 2. Observed trajectories of general fatigue
--Severe general fatigue (18.4%)
- -•- - Reference group (45.5%)
- - -0- - - Increased general fatigue with mild offset (6.8%)
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to be on diuretics (ASR=2.6), or psychotropic medication (ASR=5.7), and to be
in higher NYHA-class (ASR=3.8).
Regarding general fatigue groups, departure from independence was
only observed in the low and the severe fatigue groups (Table 2: numbers in
bold). Patients in the low general fatigue group were less likely to be physically
inactive (ASR= -2.6), to be in higher NYHA-class (ASR= -2.2), to be on
psychotropic medication (ASR= -2.8), and to have low exercise capacity (ASR=
-4.0). Patients in the severe general fatigue were more likely to be smokers
(ASR=3.2), to be physically inactive (ASR=4.3), in a higher NYHA-class
(ASR=2.0), and to have low exercise capacity (ASR= 3.1).
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Table 1. Baseline characteristics stratified by exertion fatigue class*
Variable Total Low exertion Mild exertion Reference Increased Increased Severe p-value
Fatigue fatigue group exertion exertion exertion
fatigue with fatigue with fatigue
mild offset moderate
(n=39) (n=68) (n=96) offset (n=35)
(n=20) (n=52)
Male sex 70.0 (217) 82.1 (32) 85.3 (58) 64.6 (62) 65.0(13) 67.3 (35) 48.6 (17) <.001
Age260 72.6 (225) 48.7 (19) 72.1 (49) 76.0 (73) 85.0 (17) 75.0 (39) 80.0 (28) .01
Having no partner 71.3 (221) 79.5 (31) 80.9 (55) 66.7 (64) 60.0(12) 69.2 (36) 65.7 (23) .20
Low educational level 15.2 (47) 17.9 (7) 22.1 (15) 12.5 (12) 25.0 (5) 9.6 (5) 8.6 (3) .21
Smoking 22.6 (70) 17.9 (7) 22.1 (15) 19.8 (19) 15.0 (3) 32.7 (17) 25.7 (9) .44
Obesity (BMI>30) 27.7 (86) 12.8 (5) 20.6 (14) 35.4 (34) 20.0 (4) 28.8 (15) 40.0 (14) .03
Ischemic etiology 53.9 (167) 46.2 (18) 54.4(37) 60.4 (58) 35.0 (7) 51.9 (27) 57.1 (20) .34
Cardiac historyt 57.1 (177) 48.7 (19) 54.4(37) 60.4 (58) 45.0 (9) 55.8 (29) 71.4 (25) .31
Physical inactivity 43.2 (134) 35.9 (14) 23.5 (16) 45.8 (44) 25.0 (5) 50.0 (26) 82.9 (29) <.001
Hypertension 37.4 (116) 15.4 (6) 41.2(28) 37.5 (36) 40.0 (8) 40.4 (21) 48.6 (17) .06
Hypercholesterolemia 47.7 (148) 35.9 (14) 45.6 (31) 53.1 (51) 30.0 (6) 55.8 (29) 48.6 (17) .20
Diabetes 23.9 (74) 5.1 (2) 23.5(16) 27.1 (26) 15.0 (3) 34.6 (18) 25.7 (9) .03
Comorbidities* 35.2 (109) 23.1 (9) 26.5 (18) 43.8 (42) 20.0 (4) 34.6 (18) 51.4 (18) .02
LVEF<30% 40.0 (124) 41.0 (16) 39.7 (27) 41.7 (40) 45.0 (9) 36.5 (19) 37.1 (13) .98
NYHA-class III/IV 39.4 (122) 15.4 (6) 25.0 (17) 46.9 (45) 40.0 (8) 42.3 (22) 68.6 (24) <.001
ACE-inhibitors 71.9 (223) 76.9 (30) 66.2 (45) 76.0 (73) 65.0 (13) 71.2 (37) 71.4 (25) .72
Diuretics 73.2 (227) 56.4 (22) 73.5 (50) 76.0 (73) 80.0 (16) 65.4 (34) 91.4 (32) .01
Beta blocker 68.7 (213) 79.5 (31) 69.1 (47) 69.8 (67) 80.0 (16) 55.8 (29) 65.7 (23) .18
Statins 51.0 (158) 12.8 (5) 20.6 (14) 35.4 (34) 20.0 (4) 28.8 (15) 40.0 (14) .45
Aspirin 43.5 (135) 48.7 (19) 50.0 (34) 43.8 (42) 30.0 (6) 34.6 (18) 45.7 (16) .44
Psychotropic medication 12.6 (39) 5.1 (2) 2.9 (2) 12.5 (12) 5 (1) 13.5 (7) 42.9 (15) <.001
SMWT<30Om 41.6 (129) 10.3 (4) 19.1 (13) 49.0 (47) 30.0 (6) 51.9 (27) 91.4 (32) <.001
* Numbers in bold represent an absolute adjusted standardized residual > 2.0
t History of MI, CABG, PCI
* Stroke, COPD, peripheral arterial disease, renal insufficiency
Table 2. Baseline characteristics stratified by general fatigue class*
Variable Total Low general Reference Increased Severe general p-value
Fatigue Group general fatigue fatigue
with mild offset
(n=91) (n=141) (n=21) (n=57)
Male sex 70.0 (217) 75.8 (69) 70.2 (99) 66.7 (14) 61.4 (35) .31
Age260 72.6 (225) 70.3 (64) 74.5 (105) 76.2 (16) 70.2 (40) .85
Having no partner 71.3 (221) 74.7 (68) 72.3 (102) 57.1 (12) 68.4 (39) .41
Low educational level 15.2 (47) 20.9 (19) 14.2 (20) 19.0 (4) 7.0 (4) .13
Smoking 22.6 (70) 18.7 (17) 19.1 (27) 19.0 (4) 38.6 (22) .02
Obesity (BMI>30) 27.7 (86) 24.2 (22) 27.7 (39) 28.6 (6) 33.3 (19) .69
Ischemic etiology 53.9 (167) 47.3 (43) 57.4 (81) 47.6 (10) 57.9 (33) .39
Cardiac historyt 57.1 (177) 50.5 (46) 60.3 (85) 42.9 (6) 64.9 (37) .15
Physical inactivity 43.2 (134) 31.9 (29) 40.4 (57) 42.9 (9) 68.4 (39) <.001
Hypertension 37.4 (116) 35.2 (32) 37.6 (53) 38.1 (8) 40.4 (23) .94
Hypercholesterolemia 47.7 (148) 42.9 (39) 49.6 (70) 57.1 (12) 47.4 (27) .61
Diabetes 23.9 (74) 19.8 (18) 22.0 (31) 33.3 (7) 31.6 (18) .26
Comorbiditiest 35.2 (109) 35.2 (32) 37.6 (53) 19 (4) 35.1 (20) .43
LVEF<30% 40.0 (124) 37.4 (34) 42.6 (60) 38.1 (8) 38.6 (22) .87
NYHA-class III/IV 39.4 (122) 29.7 (27) 40.4 (57) 42.9 (9) 50.9 (29) .05
ACE-inhibitors 71.9 (223) 68.1 (62) 73.0 (103) 81.0 (17) 71.9 (41) .66
Diuretics 73.2 (227) 67.0 (61) 75.9 (107) 71.4 (15) 77.2 (44) .43
Beta blocker 68.7 (213) 73.6 (67) 68.1 (96) 61.9 (13) 64.9 (37) .60
Statins 51.0 (158) 50.5 (46) 54.6 (77) 57.1 (12) 40.4 (23) .30
Aspirin 43.5 (135) 38.5 (35) 46.8 (66) 57.1 (12) 38.6 (22) .29
Psychotropic medication 12.6 (39) 4.4 (4) 15.6 (22) 9.5 (2) 19.3 (11) .03
SMWT<30Om 41.6 (129) 24.2 (22) 46.1 (65) 38.1 (8) 59.6 (34) <.001
* Numbers in bold represent an absolute adjusted standardized residual > 2.0
t History of MI, CABG, PCI
* Stroke, COPD, peripheral arterial disease, renal insufficiency
Predictors of fatigue trajectories
Multivariate predictors of exertion fatigue trajectories are shown in
Table 3. Multinomial logistic regression analysis revealed that younger patients,
patients without diabetes mellitus or other comorbidities, and patients with a
preserved exercise capacity were more likely to be in the low exertion fatigue
class as compared to the reference group, whereas patients in NHYA-class
III/IV were less likely to be in the low exertion fatigue class (Table 3a).
Furthermore, male, physically active patients without comorbidities and
impaired exercise capacity were more likely to be in the mild exertion fatigue
class as compared to the reference group. Finally, female, physically inactive
patients on psychotropic medication and with impaired exercise capacity were
more likely to be in the severe exertion fatigue group (Table 3a).
Patients with a preserved exercise capacity and not on psychotropic
medication were more likely to be in the low general fatigue class as compared
to the reference group (Table 3b). In contrast, physically inactive, smoking
patients were more likely to be in the severe general fatigue class. An
additional analysis controlling for disease severity (LVEF) did not alter the
results reported in Table 3.
Trajectories of fatigue and CHF prognosis
The mean follow-up period was 28.3 months (SD=11.8). During this
period, 50 patients (16.6%) had died. Older age, being physically active and
lower LVEF were associated with a higher incidence of mortality (Table 4).
Obesity showed a trend towards significance. Of note, being physically active
was only significantly associated with mortality in multivariate analysis, and
may therefore represent a suppressor effect.
A first Cox regression model showed that both low exertion fatigue and
severe exertion fatigue predicted mortality beyond 12-month follow-up (Table
4a, and Figure 3a). Compared to the reference group (mortality rate = 19%),
patients in the low exertion fatigue class had a decreased mortality rate (3%;
HR=0.12; 95%CI 0.02-0.93, p=.04), and patients in the severe exertion
fatigue class an increased mortality rate (29%; HR=2.59; 95%CI 1.09-6.16,
p=.03). A second Cox regression model showed that severe general fatigue
predicted mortality beyond 12-month follow-up (Table 4b, and Figure 3b).
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Patients in the severe general fatigue class had an increased risk for mortality
as compared to the reference group (mortality rate = 28% vs. 14%; HR=3.20;
95%CI 1.62-6.31, p=.001).
Table 3. Multivariate predictors of fatigue class*
(3a) Exertion fatigue class
Increased
Increased exertion
Low exertion Mild exertion exertion fatigue with Severe
Fatigue fatigue fatigue with moderate exertion
mild offset offset fatigue
Variable OR p OR p OR p    OR p OR    p
Male sex 2.56 .08 3.32 .006 ns ns ns ns 0.40 .08
Age260 0.35 .02 ns ns ns ns ns ns ns ns
Obesity, BMI>30 ns ns ns ns ns ns ns ns ns ns
Physical inactive ns ns 0.41 .02 ns ns ns ns 6.71 .001
Diabetes 0.21 .05 ns ns ns ns ns ns ns ns
Comorbiditiest O.31 .02 O.44 .03 0.33 .07 ns ns ns ns
NYHA-cl. III/IV 0.32 .04 0.48 .06 ns ns ns ns ns ns
Diuretics ns ns ns ns ns ns ns ns ns ns
Psychotropics ns ns 0.22 .07 ns ns ns ns 5.43 .003
SMWT<30Om 0.22 .02 0.39 .02 ns ns ns ns 9.62 .001
(3b) General fatigue class
Increased
Low general general fatigue Severe general
Fatigue with mild offset fatigue
Variable OR           p           OR           p           OR           p
Smoking ns ns ns ns 3.03 .002
Physical inactivity ns ns ns ns 2.96 .002
NYHA-class III/IV ns ns ns ns ns ns
Psychotropics 0.28 .03 ns ns ns ns
SMWT<30Om 0.42 .007 ns ns ns ns
*Significant levels >0.1 are displayed as ns, i.e. not significant
tStroke, COPD, peripheral arterial disease, renal insufficiency
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Table4. Trajectories of fatigue and CHF prognosis (multivariate)
(4a) Model including exertion fatigue
Variable HR 95%CI p-value
Male sex 1.67 0.85-3.31 .14
Age260 3.23 1.26-8.26 .01
Obesity (BMI>30) 0.48 0.23-1.02 .06
Physical inactivity 0.43 0.21-0.85 .02
Diabetes 1.23 0.63-2.37 .55
LVEF<30% 2.17 1.22-3.87 .009
Low exertion fatigue 0.12 0.02-0.93 .04
Mild exertion fatigue 0.59 0.27-1.32 .20
Increased exertion fatigue 0.65 0.19-2.21 .49
with mild offset
Increased exertion fatigue 1.03 0.44-2.41 .95
with moderate offset
Severe exertion fatigue 2.59 1.09-6.16 .03
(4b) Model including general fatigue
Variable HR 95%CI p-value
Male sex 1.22 0.63-2.36 .55
Age260 3.70 1.45-9.47 .006
Obesity (BMI>30) 0.53 0.25-1.15 .11
Physical inactivity 0.56 0.31-1.02 .06
Diabetes 1.26 0.64-2.46 .51
LVEF<30% 2.20 1.24-3.90 .007
Low general fatigue 0.89 0.42-1.89 .75
Increased general fatigue 1.71 0.58-5.07 .33
with mild offset
Severe general fatigue 3.20 1.62-6.31 .001
An additional analysis controlling for use of psychotropic medication
(p>0.5 in both models) did not significantly alter the model results displayed in
Table 4. A final analysis showed that when exertion fatigue and general fatigue
were entered in the multivariate model simultaneously, both severe exertion
fatigue (HR=2.90; 95%CI 1.14-7.36, p=.03) and severe general fatigue
(HR=3.00; 95%CI 1.47-6.14, p=.003) remained significant predictors of
mortality. Similar, the protective effect of low exertion fatigue (HR=0.12;
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95%CI 0.02-0.99, p=.05) remained significant as well. This result suggests
that independently from each other both types of fatigue add to the risk of
mortality in CHF.
Figure 3a. Event free survival stratified by exertion fatigue class
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DISCUSSION
To our knowledge, this is the first study to examine the course of
symptoms of fatigue in patients with CHF. Similar to previous studies (5,12),
we differentiated between exertion and general fatigue, and found six distinct
trajectories for exertion fatigue and four distinct trajectories for general
fatigue. Multinomial logistic regression analysis revealed that sex, age, physical
inactivity, diabetes mellitus, comorbidities, NYHA-class, exercise capacity, and
psychotropic medication were predictors of exertion fatigue, varying according
to classes. Predictors of general fatigue, again varying according to classes,
comprised smoking, physical inactivity, and exercise capacity. Cox regression
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showed that patients in the severe exertion fatigue class, and severe general
fatigue class independently had an almost three-fold increased risk for
mortality as compared to the reference group. Patients in the low exertion
fatigue group had a decreased risk for mortality.
Fatigue is considered as one of the most important symptoms affecting
patients' quality of life. However, fatigue remains under recognized in clinical
practice (24,25), as well as an unresolved issue in CHF (12). In the current
study, we were able to further refine our understanding of the course of fatigue
in CHF, and to characterize most of the trajectories by means of baseline
variables. Overall, patients with low/mild levels of exertion/general fatigue
were characterized by relative good physical health (no diabetes mellitus, no
comorbidities, no physical inactivity, good exercise capacity) and psychological
health (no psychotropic medication), whereas the opposite was true for
patients with high levels of fatigue. Age and gender effects were found for
exertion fatigue. However, we were unable to describe the trajectories that
showed an increase of fatigue over time (increased exertion fatigue with mild
offset, increased exertion fatigue with moderate offset, and increased general
fatigue with mild offset). An explanation for this could be 1) that the groups
were relatively small and therefore lacked statistical power to reveal significant
differences, and 2) that the overall response levels of fatigue in these
trajectories were more similar to the reference group as compared to the more
extreme groups, resulting in smaller differences with respect to baseline
variables.
From a clinical point of view, knowledge about factors characterizing
trajectories that display changes in fatigue over time is important as they point
to targets for intervention. Importantly, the findings of the present study
indicate that fatigue trajectories are differently related to an increase or
decrease in mortality rate. This finding provides further fuel to the 'debate'
whether the experience of fatigue is an important factor in itself or merely an
unwelcome byproduct of disease progression (26). In previous studies, we
have shown that fatigue was associated with rehospitalization (2) and with the
combined endpoint of rehospitalization and death (5). A problem with
rehospitalization as an outcome measure is its semi-objective nature since the
decision to rehospitalize is not solely based on objective diagnostic measures
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but also on symptom presentation and symptom interpretation. Therefore, it is
important to note that, in the present study, both exertion and general fatigue
independently predicted mortality in CHF, above and beyond disease severity
and other clinical risk factors. Large-scale studies should give a more in-depth
insight into the differential effect of the fatigue trajectories on mortality.
The mechanisms through which fatigue may exert its effect on
mortality are unclear. Future studies should assess physiological measures that
are known to be abnormal in CHF patients and that are relevant with respect to
fatigue, for example measures of abnormal muscle metabolism and an
enhanced ergo reflex response (6,7), but also inflammatory markers may be
an interesting avenue for research in this regard (27,28). Increased fatigue
may also have impact on the patient's ability for self-care, which has been
associated with poor prognosis in CHF (29).
The results of the present study advocates the use of a latent growth
mixture modeling approach in clinical cardiology research because it allows for
the identification of subgroups with distinct developmental patterns. As such,
this approach provides additional information beyond that from studying
prevalence rates or change scores. A latent class approach has also been used
in previous studies (14,22,23,30,31), however without the inclusion of a
random intercept. Similar to our studies, these studies also found support for
multiple rather than single trajectories, although they examined depressive
symptoms (14,22,30), anxiety (23), and quality of life (31), but not fatigue.
This study has a number of limitations. First, the cardiologist or heart
failure nurses asked patients to participate in the study, and this interaction
pattern might have influenced patient selection. Second, the examined
predictors of the fatigue trajectories were only assessed once. Nevertheless,
the strengths of the current study were the repeated assessment of fatigue
over time, the prospective design examining the course of fatigue over time
using a state-of-the-art modeling approach, and the use of an objective
medical outcome. Finally, we used reliable and valid measures of both exertion
and general fatigue.
In summary, we found six distinct trajectories for exertion fatigue, and
four distinct trajectories for general fatigue in patients with CHF. Several
predictors, varying according to classes, could be identified with age, sex,
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physical inactivity, comorbidities, exercise capacity, and psychotropic
medication use being the most prominent ones. Severe exertion fatigue and
severe general fatigue independently predicted an increased mortality risk
beyond 12-month follow-up, whereas low exertion fatigue was associated with
a decreased mortality risk. Future studies are warranted to confirm these
findings, given that this was the first study to examine the course of fatigue in
CHF patients. The results of the present study may help identify distinct groups
of patients with potentially differential risks of adverse health outcomes, guide
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CHAPTER 9:
Somatic/affective depression predicts mortality in chronic heart
failure: Can this be explained by co-varying symptoms of
fatigue?
Otto RF Smith, Nina Kupper, Angdlique A. Schiffer, Johan Denollet
Submitted for publication
ABSTRACT
Aim: We previously showed that somatic/affective symptoms of depression
predict mortality in chronic heart failure (CHF), but symptoms of fatigue that
are common to both conditions may confound this association. We therefore
examined whether fatigue can explain away the relationship between
somatic/affective depression and increased risk of mortality in CHF patients.
Methods: At baseline, 380 consecutive CHF patients were assessed for
symptoms of depression, exertion fatigue and general fatigue. Demographic
and clinical data were obtained from the patients' medical records or treating
cardiologist. The primary endpoint was mortality after a mean follow-up of 2.3
years (SD=1 year). Results: At follow-up, 63 patients (16.6%) had died.
Exertion fatigue (HR=1.04; 95%CI 1.01-1.06, p=.003), but not general
fatigue, was associated with an increased risk of mortality in CHF. Multivariate
Cox regression analysis revealed that somatic/affective symptoms of
depression (HR=1.09; 95%CI 1.002-1.19, p=.04) were independently
associated with increased mortality risk, and that this association could not be
explained by exertion fatigue (HR=1.02; 95%CI 0.99-1.05, p=.23).
Conclusion: The adverse effect of somatic/affective depression on prognosis in
CHF was not confounded by exertion fatigue. Behavioral interventions should
not only focus on fatigue but also on other somatic/affective manifestations of
depression in patients with CHF.
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INTRODUCTION
Depression and depressive symptoms have been related to increased
mortality in patients with chronic heart failure (CHF) (1-3). Recently, it was
shown that the relation between depression and outcome in cardiac disease
may be explained by the somatic/affective symptoms of depression, rather
than cognitive/affective symptoms of depression (4-8), suggesting that it is
important to take into account the differential effect of cognitive/affective and
somatic/affective symptoms of depression.
Symptoms of fatigue are highly prevalent among CHF patients (9), and
are often considered as one of the key symptoms affecting quality of life (10).
In addition, fatigue has been associated with poor outcome in CHF (11-13). In
post-myocardial infarction patients, it has been suggested that an explanation
for the association between depression and poor outcome may be co-existing
symptoms of fatigue (14), as fatigue/energy loss is one of the core
characteristics of the somatic/affective domain of depression (15).
However, to the best of our knowledge, this has never been examined
in the context of CHF. Therefore, the aim of the present study was to examine
whether fatigue may explain away the relationship between somatic/affective
symptoms of depression and poor prognosis in patients with CHF.
METHODS
Patients
The sample included 380 consecutive CHF patients, with systolic heart failure
and a left ventricular ejection fraction (LVEF) 540%, visiting the heart failure
outpatient clinic of the TweeSteden Hospital, Tilburg, the Netherlands. Patients
with diastolic heart failure (i.e., those with an intact pump function during
systole, and diminished filling capacity during diastole), age 280 years,
myocardial infarction in the month prior to inclusion, other life-threatening
comorbidities (e.g., chemotherapy treated cancer), and no or insufficient
understanding of spoken and written Dutch language were excluded. All 380
patients completed a questionnaire at baseline. The study protocol was
approved by the local medical ethics committee in Tilburg, the Netherlands.
The study was conducted conform to the Helsinki Declaration and every patient
provided written informed consent.
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The majority of subjects was male, married, non-smokers, and not
academically educated (Table 1). About half the sample was classified as
NYHA-class III/IV, had a cardiac history, had comorbidities, and ischemic CHF.
Only a minority of the sample were overweight or anemic. Diuretics, ACE-
inhibitors, and beta-blockers were the most prescribed medications.
Demographic and clinical variables
Demographic variables included sex, age, educational level, and marital
status. Clinical variables comprised LVEF, NYHA class, etiology of CHF,
diabetes, cardiac history (i.e. MI, PCI, CABG), smoking status, BMI,
comorbidity (i.e. stroke, COPD, hypertension, peripheral arterial disease, renal
insufficiency), and cardiac medication. Information on clinical variables was
obtained from the medical records and from the treating cardiologist.
Somatic/affective symptoms of depression
Symptoms of depression were measured by means of the Beck
Depression Inventory (BDI) (16). Each item is rated on a 0-3 scale; a total
score is obtained by summing together all the items. The BDI is a reliable and
well-validated measure of depressive symptomatology (17), and is the most
widely used self-report measure of depression (18). The somatic/affective
domain score (16) was calculated by summing together BDI items 14-21, and
comprises symptoms that refer to somatic manifestations of depression (e.g.,
weight changes, sleep problems). The remaining items refer to
cognitive/affective manifestations of depression (e.g., sadness, guilt).
Symptoms of fatigue
Previous research suggest to differentiate between exertion and
general fatigue (19); the former referring to fatigue directly related to the
performing of activities in daily living, and the latter to an overwhelming,
sustained sense of exhaustion that does not necessarily have a relationship
with exertion. The Dutch Exertion Fatigue Scale (DEFS) assesses exertion
fatigue by means of nine items (20). Items are answered with five response
alternatives ranging from 0 (no) to 4 (yes) with total scores ranging from 0 to
36. Chronbach's alpha is high (a=91). The Fatigue Assessment Scale (FAS) was
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used to assess symptoms of general fatigue (21), and consists of 10 items, all
answered on a 5-point Likert scale, ranging from 0 (never) to 4 (always). A
total score is calculated by adding all items, with total scores ranging from 0 to
40. The questionnaire has good internal validity and the reliability of this
instrument is high (a=.90).
Clinical endpoints
The primary endpoint in this study was all-cause mortality. Information
on mortality (date and cause of death) was collected by checking the hospital's
electronic system/the patients' medical records or by contacting the GP.
Statistical analyses
Prior to further statistical analyses, NYHA class, etiology of heart
failure, and cardiac history were recoded into dichotomous variables. Discrete
variables were compared with the chi-square test and continuous variables with
Student's t test for independent samples. Pearson correlations were calculated
to evaluate the relations between depression and fatigue. Cox regression
analyses was used to examine the impact of somatic/affective symptoms of
depression on all-cause mortality while controlling for fatigue. Given the
number of fatal events, a maximum of five additional, well-established risk
factors was selected a priori in order to obtain reliable estimates in multivariate
analyses, i.e. sex, age, NYHA class, smoking, and LVEF.
RESULTS
Clinical predictors of mortality
The mean follow-up period was 2.3 years (SD=1 year). During this
period, 63 patients (16.6%) had died. Higher age, NYHA-class III/IV, lower
LVEF, and longer time since diagnosis were associated with a higher incidence
of mortality (Table 1). Male sex, smoking, prescription of diuretics, and no
prescription of beta blockers showed a trend towards significance.
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Table 1. Baseline characteristics stratified by incidence of fatal events
Total No fatal events Fatal events p-value
(n=380) (n=317) (n=63)
Demographics
Age, mean iSD 65.8 i 10.4 65.1 t 10.8 69.1 i 7.1 <.001
Male sex, % (n) 72.1 (274) 70.3 (223) 81.0 (51) .09
Having a partner, % (n) 72.1 (274) 72.9 (231) 68.3 (43) .46
No academic education, % (n) 85.8 (326) 84.9 (269) 90.5 (57) .24
Disease characteristics
Ischemic etiology, % (n) 53.9 (205) 53.6 (170) 55.6 (35) .78
LVEF, Mean + SD 30.8 i 6.9 31.4 1 6.7 27.5 i 7.1 <.001
NYHA class III/IV, % (n) 39.7 (151) 36.6 (116) 55.6 (35) .005
Time since diagnosis, yrs iSD 3.3 (3.9) 3.1 (3.8) 4.3 (4.2) .03
Cardiac historyt, % (n) 57.4 (218) 56.5 (179) 61.9 (39) .43
Biomedical risk factors
Smokers, % (n) 23.9 (91) 22.1 (70) 33.3 (21) .06
BMI, mean iSD 28.1 k 5.3 28.2 i 5.2 27.3 f 5.8 .19
Comorbidity*, % (n) 58.2 (221) 56.8 (180) 65.1 (41) .22
Diabetes, % (n) 24.7 (94) 23.3 (74) 31.7 (20) .16
Medication
ACE-inhibitor, % (n) 71.6 (272) 72.6 (230) 66.7 (42) .34
AT-II antagonists, % (n) 18.4 (70) 17.0 (54) 25.4 (16) .12
Diuretics, % (n) 72.9 (277) 71.0 (225) 82.5 (52) .06
Beta blockers, % (n) 67.1 (255) 69.1 (219) 57.1 (36) .07
Statins, % (n) 51.1 (194) 51.1 (162) 50.8 (32) .96
Calcium antagonists, % (n) 11.3 (43) 11.4 (36) 11.1 (7) .96
Aspirin, % (n) 40.8 (155) 41.0 (130) 39.7 (25) .85
Psychotropics, % (n) 11.6 (44) 12.3 (39) 7.9 (5) .32
t History of MI, CABG, PCI
* Stroke, COPD, hypertension, peripheral arterial disease, renal insufficiency
Association between fatigue and depression
Exertion fatigue and general fatigue were both significantly associated
with total depressive symptoms (BDI total score: r=.54, p<.001 and r=.66,
p<.001; respectively), the somatic/affective subscale (r=.62; p<.001 resp.
r=.65; p<.001), and the cognitive/affective subscale (r=.39; p<.001 resp.
r=.55; p<.001) of the BDI. As expected, the association between exertion
fatigue and cognitive/affective symptoms of depression was moderate,
suggesting exertion fatigue is representing physical aspects of fatigue, whereas
general fatigue seems to capture both physical and mental aspects of fatigue.
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Figure 1. Mean levels of exertion and general fatigue stratified by survival
status















Exertion fatigue General fatigue
Exertion fatigue, depression and mortality
Cox regression analysis revealed that exertion fatigue was associated
with mortality in univariate analysis (HR=1.04; 95%CI 1.01-1.06, p=.003),
whereas general fatigue (HR=1.02; 95%CI 0.99-1.05, p=.25) was not. As
displayed in figure 1, mean levels of exertion fatigue were significantly higher
in patients that died. After adjusting for sex, age, NYHA class, smoking, and
LVEF, exertion fatigue (HR=1.04; 95%CI 1.01-1.06, p=.003) remained a
significant predictor of mortality in CHF. As reported previously, patients high
on somatic/affective depression symptoms also had a significantly increased
mortality risk compared to non-depressed patients (5-7).
To determine whether the effect of somatic/affective symptoms of
depression on mortality can be explained by exertion fatigue, we added
exertion fatigue to the multivariate model including the somatic/affective
depression domain score, sex, age, NYHA class, smoking, and LVEF. Cox
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regression analysis revealed that adding exertion fatigue (HR=1.02; 95%CI
0.99-1.05, p=.23) did not significantly alter the effect of somatic/affective
symptoms of depression (HR=1.09; 95%CI 1.002-1.19, p=.04) on mortality
(Table 2).
Table 2. Predictors of mortality in CHF (multivariate)
HR 95%CI p-value
Male sex 1.45 0.75-2.78 .27
Age 1.04 1.01-1.07 .006
Smoking 1.79 1.03-3.11 .04
NYHA-class III/IV 1.10 0.63-1.90 .74
LVEF 0.94 0.91-0.98 .002
Exertion fatigue 1.02 0.99-1.05 .23
Somatic/affective symptoms of depression 1.09 1.01-1.19 .04
DISCUSSION
The present findings suggest that the effect of somatic/affective
symptoms of depression on mortality risk in patients with CHF cannot be
explained away by co-varying symptoms of fatigue. Hence, this provides
further evidence for the notion that somatic/affective symptoms of depression
should be examined in their own right in relation to cardiovascular prognosis.
Lately, it has become apparent that depression in cardiovascular disease is
atypical (22), and that the prognostic value for hard medical outcomes of the
cognitive/affective dimension of depression is less evident than that for
somatic/affective symptoms (4,6-8). Depressed mood, however, does remain
relevant and important in cardiovascular disease, in particular in terms of
affecting the patients' quality of life (23).
Apart from depression, it was shown that exertion fatigue, but not
general fatigue, predicted mortality in CHF. Previously, it was demonstrated
that exertion fatigue was primarily determined by physical aspects of CHF such
as hypertension, and exercise capacity (19), suggesting that exertion fatigue
reflects the direct physical consequences of the disease itself. The current
study showed that exertion fatigue was a predictor of mortality in CHF
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independent from reduced cardiac output. Hence, the origin of exertion fatigue
may lie elsewhere. Two recent reviews suggest that skeletal muscle
abnormalities in CHF might be responsible for the sensation of fatigue (24,25),
which in turn could be a result of a combination of disuse, impaired perfusion,
and catabolic myopathy (25). Future studies should examine whether exertion
fatigue relates to these factors.
Exertion fatigue did not explain the association between
somatic/affective symptoms of depression and mortality in CHF suggesting that
a broader array of somatic symptoms is important in predicting CHF mortality.
In line with what was discussed for exertion fatigue, somatic/affective
symptoms of depression (e.g. fatigue, loss of appetite, loss of sexual pleasure)
might reflect several underlying physiological processes that are not generally
accounted for in standard prognostic models. Immune factors are important in
this regard, because they are known to predict poor outcome in CHF (26-29)
and have also been associated with depressive symptoms (30,31). It would
therefore be interesting to examine the predictive value of somatic/affective
symptoms while controlling for immune factors. However, it is also possible
that somatic/affective symptoms reflect distinct manifestations of depression
that are perceived by cardiac patients to be more relevant to describe their
mental health status (32) as compared to the more obvious cognitive
symptoms of depression (22).
The findings of the present study have important implications for
treatment of fatigue and depression in CHF. Previous work has shown that
exercise training reduces autonomic derangement, neurohumoral activation,
and symptoms of fatigue and dyspnoea (33,34), and would therefore be a
viable option for treatment of fatigue in CHF. However, the findings of the
present study suggest that additional behavioral interventions may be needed
to reduce the risk associated with other somatic/affective manifestations of
depression. Importantly, recent research indicates that somatic/affective
symptoms of depression are often overlooked in cardiac patients; as a result,
depression is recognized in fewer than 1 in 3 cardiac patients (8). Our findings
thus also call for a greater awareness of somatic/affective symptoms of
depression in CHF patients.
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A number of limitations should be mentioned. The follow-up period was
relatively short. Furthermore, the sample could be biased by mobility and
younger age, because participating patients were required to visit the
outpatient clinic. Finally, the sample used in this study was quite
heterogeneous, as end stage CHF patients as well as newly diagnosed CHF
patients were included. However, this is also a strength, as it reflects "the real
world" of CHF patients seen in daily clinical practice. Other strengths of the
study include the use of valid and reliable questionnaires to assess symptoms
of fatigue, and that this is the first study to examine the prognostic value of
fatigue and somatic symptoms of depression together in patients with
established CHF.
In summary, somatic/affective symptoms of depression predicted
mortality in CHF, and this effect was not confounded by exertion fatigue. These
findings indicate that clinicians should be aware of somatic/affective symptoms
of depression, and that behavioral interventions should not only focus on
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General summary and discussion
This thesis presents the results of several studies examining the role of
psychological factors in chronic heart failure (CHF). In this chapter, the main
findings are presented and implications for research and clinical practice are
discussed.
Vital exhaustion in chronic heart failure
Previous studies have examined the role of vital exhaustion in coronary
artery disease (CAD). It has been shown that vital exhaustion predicts new
onset of coronary events (1,2) as well as recurrent coronary events (3,4).
Furthermore, vital exhaustion has been linked to a range of physiological
parameters that could potentially explain the association between vital
exhaustion and adverse outcome in CAD (5-19). However, an intervention
study aimed to reduce vital exhaustion in percutaneous coronary intervention
(PCI) patients did not improve prognosis, suggesting that vital exhaustion is
not part of a causal chain but merely a reflection of ongoing physiological
processes (20). Vital exhaustion has not been studied previously in CHF.
The first part of this thesis covered several aspects of the relationship
between vital exhaustion and CHF and aimed to examine the nature and course
of vital exhaustion in CHF, as well as the interrelationships between vital
exhaustion and disease stage within CAD and other prevalent and influential
psychological factors.
In chapter 2, the nature of vital exhaustion in CHF was investigated.
Principal component analysis revealed four essential features which are, in
order of importance, fatigue, cognitive-affective symptoms of depression, sleep
problems, and lack of concentration. This result was in line with a previous
study in MI patients (21). The components of vital exhaustion show
considerable similarity to symptom dimensions found in major depression.
However, their emphasis is different. In vital exhaustion, the starting point is a
state of unusual tiredness (1) which is often accompanied by cognitive-
affective depressive symptoms, sleep problems, and lack of concentration,
whereas the core symptoms of depression are low mood and loss of interest
that often go together with fatigue, sleep problems, and loss of appetite (22).
The study presented in chapter 2 supports this notion by showing that 1)
fatigue explains more of the variance in vital exhaustion as compared to the
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other subcomponents, and 2) low mood and loss of interest are not explicitly
part of the cognitive-affective depressive symptoms component of the
Maastricht Questionnaire that assesses vital exhaustion. All in all, this part of
the study indicates that in spite of previous statements (23), vital exhaustion
and depression are not simply interchangeable.
Subsequently in chapter 2, the individual components of vital
exhaustion (fatigue, cognitive-affective symptoms of depression, sleep
problems, and lack of concentration) were used to identify distinct profiles of
vital exhaustion in CHF patients: a subgroup without vital exhaustion scoring
low on all components, a first subgroup with vital exhaustion scoring high on
fatigue and lack of concentration, but low on depressive symptoms and sleep
problems, and a second subgroup with vital exhaustion scoring high on all
components. Both vitally exhausted groups displayed higher levels of impaired
health status as compared to the subgroup without symptoms of vital
exhaustion. Exhausted patients manifesting all symptoms were more likely to
be rehospitalized than patients without vital exhaustion. Vitally exhausted
patients without depressive symptoms and sleep problems also showed a
tendency for more hospitalizations but this was not statistically significant.
These results indicate that focusing on symptoms of depression alone may not
be sufficient, since patients with elevated levels of fatigue and lack of
concentration, but with a relative absence of depressive symptoms and sleep
difficulties, also had impaired health status, and showed a tendency towards an
increased risk for rehospitalization. Focusing on clusters of psychological risk
factors rather than a single risk factor has been advocated by others as a more
detailed examination of symptom profiles may lead to better informed
development of more effectively timed and more specifically tailored behavioral
interventions (24,25). This "subclinical" group may therefore be a relevant
target for future interventions, which corresponds to findings from an earlier
profile study in MI patients (26).
In chapter 3, the main components of vital exhaustion, fatigue and
depressive symptoms were used as outcome measures at 12-month follow-up
in a combined sample of CHF and PCI patients. The results indicated that
ischemic heart disease stage was not associated with the core symptoms of
vital exhaustion. In other words, CHF patients did not report more symptoms of
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fatigue and depression as compared to PCI patients. In contrast, Type D
personality did predict symptoms of vital exhaustion at 12-month follow-up,
and this effect was not moderated by ischemic heart disease stage. Although it
may seem counterintuitive that a more severe disease stage is not associated
with more symptoms of fatigue and depression, this result may indicate that
the physiological course of a disease is not necessarily on par with the
psychological course. CHF patients often have a longer and more severe
cardiac history as compared to PCI patients. Therefore, they may be better
accustomed to the disease, which in turn could mask the objectively increased
physical deterioration. More importantly, this study revealed that symptom
perception is, at least partly, dependent on psychological factors. This
knowledge could potentially be very relevant for clinicians and other health
care professionals when evaluating the patient's symptom presentation.
Chapter 4 focused on the course of vital exhaustion in a combined
sample of MI and CHF patients over a 12 month period. The results supported
the existence of multiple trajectories rather than one. Latent class mixture
modeling revealed four different trajectories of vital exhaustion: low vital
exhaustion, decreasing vital exhaustion, increasing vital exhaustion, and
severe vital exhaustion. It turned out that the majority of patients displayed
stable patterns of vital exhaustion over time, which is line with findings from
previous studies examining the trajectories of depression (27-29), and anxiety
(30).
Furthermore, a marked difference was found between sample group
(MI vs. CHF) and trajectory group membership. MI patients were more likely to
be in the increasing vital exhaustion group, whereas CHF patients were more
likely to be in the severe vital exhaustion group. Remarkably, almost half of the
total CHF sample was found in the stable severe vital exhaustion group. In both
the increasing and severe vital exhaustion groups, the likelihood of
cardiovascular events was higher as compared to the low vital exhaustion
group. These findings suggest that a significant number of patients after a MI
do not fully recover but deteriorate over time, and may represent a group of MI
patients that do not respond to standard treatment procedures, which is in line
with studies that have shown that persistence of depressive symptoms, despite
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treatment, predicts increased cardiac risk (28,31,32). In addition, most
vulnerable MI and CHF patients may differ in their patterns of vital exhaustion.
Overall, the findings of the first part of this thesis provide evidence for
the relevance of vital exhaustion in the context of CHF. First of all, it was
shown that vital exhaustion is a broader concept than fatigue, and that it is not
interchangeable with depressive symptoms. Second, profile analysis
demonstrated the relevance of subclinical presentation of symptoms of vital
exhaustion, primarily expressed as fatigue in absence of depressive symptoms.
Third, a large proportion of CHF patients displayed stable patterns of vital
exhaustion. Close to half of the CHF sample was found to have stable and
severe levels of vital exhaustion over time, and were at increased risk for
adverse cardiac events. This indicates that, despite improved treatment
modalities, a significant part of the CHF population does not improve over time
in terms of vital exhaustion, and suggests that other modes of intervention are
imperative.
Symptoms of fatigue in chronic heart failure
So far, fatigue has received little attention in the HF literature, even
though fatigue is often rated as one of the most disabling symptoms in CHF
(33). Previous studies have underlined the importance of symptoms in CHF,
both in terms of prognosis (34,35) and health status (36). Several unknown
aspects of fatigue in CHF were addressed in this thesis among which were
explaining individual differences in fatigue, investigating the course of fatigue
over time, and the interrelationship with coexisting symptoms of depression
and their impact on prognosis.
As suggested by previous studies, different types of fatigue can be
distinguished in CHF (37). In chapter 5, exertion fatigue and general fatigue
were identified as distinct types of fatigue. Exertion fatigue is directly related to
the performing of activities in daily living, whereas general fatigue reflects an
overwhelming, sustained sense of fatigue that does not necessarily have a
relationship with exertion. Although both types of fatigue are not mutually
exclusive, it is still important to distinguish between them because the origin
and relevance of exertion and general fatigue in CHF might be different, which
in turn may help to guide future (tailored) interventions. This is illustrated by
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the second part of chapter 5, in which it was shown that exertion fatigue was
primarily predicted by physical characteristics, whereas general fatigue was
predicted by both physical and psychological characteristics. Exertion fatigue
may therefore primarily be of peripheral origin, resulting from neuromuscular
dysfunction outside the central nervous system, and may therefore relate to
impaired neurotransmission in peripheral nerves and/or defects in muscular
contraction. The latter processes have been observed in CHF as well (38,39).
General fatigue might be more closely related to fatigue at a central level, and
implies alterations or abnormalities in neurotransmitter pathways within the
central nervous system, and often co-exists with psychological co-morbidities
(40,41).
Fatigue is common in other conditions as well. A substantial proportion
of patients who have had a stroke perceive fatigue as their worst or one of
their worst symptoms (42). Results of chapter 6 indicated that the Fatigue
Assessment Scale, as a measure of general fatigue, has good psychometric
properties in stroke patients. Furthermore, it was found that the levels of
general fatigue were similar in stroke patients and CHF patients but were
considerably higher compared to healthy controls, emphasizing its clinical
significance in CHF and stroke.
Levels of fatigue can change over time, but the dynamic nature of
fatigue has not been studied in the context of CHF thus far. In the study
presented in chapter 7, exertion fatigue and general fatigue were measured at
baseline and 12-month follow-up, and changes over time were linked to the
combined clinical endpoint cardiac re-admission or death beyond 12-months
follow-up. It was demonstrated that changes in exertion fatigue, but not
general fatigue, predicted adverse events beyond 12-months follow-up. Two
important lessons can be learned from this study. First, within-subject changes
of fatigue are clinically relevant, and patients that display an increase in
symptoms of fatigue should be taken seriously as they have an increased risk
for adverse events. Second, changes in exertion fatigue might be more
relevant in the context of CHF as compared to changes in general fatigue as
they may indicate worsening of heart failure.
Other than studying changes in fatigue within a total group, modern
statistical techniques allow for the identification of classes of individuals, who
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follow similar behavioral patterns over time. In chapter 8, it was shown that for
both exertion fatigue and general fatigue multiple trajectories could be
distinguished. The majority of patients displayed stable trajectories over time,
and it was shown that patients in both the severe exertion fatigue and the
severe general fatigue group had an increased risk for mortality. In contrast to
the study presented in chapter 7, general fatigue did predict poor outcome in
CHF, which can most likely be explained by the use of different study designs,
i.e. in chapter 7 changes in fatigue were studied, whereas the aim of chapter 8
was to identify distinct trajectories of fatigue over time. The results indicated
that changes over time occurred less frequent in general fatigue as compared
to exertion fatigue, reducing its power to predict adverse events. The results of
chapter 8 demonstrate that high baseline levels of both exertion and general
fatigue are not likely to decrease over time, despite optimal pharmacological
treatment, and that these groups are at increased risk for mortality.
Fatigue and depression often co-exist in patients with cardiovascular
disease (43). A recent study showed that the relation between depression and
outcome in CHF may be explained by the somatic/affective symptoms of
depression, rather than cognitive/affective symptoms of depression (44). It has
previously been suggested that an explanation for the association between
depression and poor outcome may be co-existing symptoms of fatigue (45).
However, the results of the study reported in chapter 9 do not support this
hypothesis. It was shown that somatic/affective symptoms of depression were
independently associated with increased mortality risk and that this association
could not be explained by exertion fatigue and general fatigue. This suggests
that a broader array of somatic/affective symptoms is important in predicting
CHF mortality. The somatic/affective symptoms of depression might reflect
several underlying physiological processes that are not generally accounted for
in standard prognostic models. It would be interesting to examine the
predictive value of somatic/affective symptoms while controlling for immune
factors since they are known to predict poor outcome in CHF (46), and have
also been associated with depressive symptoms (47,48). It has also been
suggested that somatic/affective symptoms of depression reflect distinct
manifestations of depression that are perceived by cardiac patients to be more
relevant to describe their mental health status (49). There is however little
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empirical support for this point of view, and clinical trials aimed to reduce
depression by psychosocial interventions or antidepressant treatment in CAD
patients have not been able to prolong survival (50-52), despite effective
treatment of depression (50,51).
Of note, before taking somatic/affective symptoms into account,
exertion fatigue, but not general fatigue, both measured at baseline, predicted
mortality in CHF. Taking into account the results from the previous chapters,
exertion fatigue seems a more consistent predictor of adverse outcomes in CHF
as compared to general fatigue. Exertion fatigue might primarily reflect the
direct consequences of CHF, and may therefore be a more relevant measure for
CHF patients in terms of predicting prognosis. In contrast, general fatigue has
a more ambiguous nature, and might not be specific enough in this regard.
All in all, the results of part B of the present thesis indicate that fatigue
is an important factor in CHF. It was shown that two types of fatigue should be
distinguished in CHF, i.e. exertion fatigue and general fatigue. Exertion fatigue
seems most relevant in terms of predicting prognosis, and can potentially be
used for risk stratification in CHF. However, exertion fatigue did not tell the
whole story. It seems that a broader array of somatic/affective symptoms of
depression should be taken into account when predicting adverse outcomes in
CHF.
Implications for research and clinical practice
Vital exhaustion
Until now, vital exhaustion had primarily been studied in CAD patients.
Vital exhaustion was shown to predict adverse outcome in this patient group,
and to be associated with a range of physiological parameters, but a behavioral
intervention aimed to reduce vital exhaustion did not lead to improved
prognosis (53). The studies presented in this thesis showed that vital
exhaustion is also an important risk marker in CHF (Chapter 3 & 4). However,
more research is needed to determine whether vital exhaustion can also qualify
as a modifiable risk factor that is a determinant that can be modified by an
intervention and reduce the probability of adverse outcomes. Several research
questions remain unanswered, the most important one being the extent to
which vital exhaustion is the result of behavior as opposed to physiological
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processes related to CHF. It seems much more plausible that vital exhaustion
can be the result of overextending oneself within a middle-aged working
population without a cardiac history. In contrast, CHF patients have to deal
with a serious condition that is often accompanied by an extensive cardiac
history and other burdensome comorbidities. Hence, vital exhaustion as a
modifiable risk factor seems less relevant in the context of CHF. Future studies
should examine this.
More research is also needed to explain vital exhaustion in CHF. Studies
in chapter 2&3 identified demographic, clinical, and psychological associates
of vital exhaustion. Future studies should include physiological measures that
are known to be abnormal in CHF patients and that are relevant with respect to
vital exhaustion, for example measures of abnormal muscle metabolism, an
enhanced ergo reflex response, and increased levels of pro-inflammatory
markers (38,39,54).
Cluster analysis revealed a subclinical group with elevated levels of
fatigue and lack of concentration, but with a relative absence of depressive
symptoms and sleep problems (Chapter 2). Evidence was found that these
patients generally have poor health status, and have a tendency towards more
hospitalizations. However, large-scale studies with hard medical endpoints are
required to obtain a more in-depth insight into the clinical relevance of this
group.
In chapter 4, different trajectories of vital exhaustion were identified
and their subsequent impact on prognosis. In this chapter, total scores of vital
exhaustion were used, but as was shown in chapter 2, vital exhaustion
comprises four different dimensions. It would be interesting to do a separate
trajectory analysis for each component, and to determine what component
turns out to be the most prominent predictor of adverse outcomes in CHF.
Identifying the most cardio-toxic components of vital exhaustion may help to
develop future interventions.
In clinical practice, recognizing symptoms of vital exhaustion is
important since they are a risk marker for poor prognosis. Information on daily
activities and engagement in physical exercise may guide intervention.
Recently, it has been shown that CHF patients may benefit from physical
exercise programs with a good balance between resting and activity being an
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important factor (55). Since the perception of vital exhaustion may also depend
on co-morbid depression, anxiety, and/or personality factors, referral to a
clinical psychologist should be set at a low threshold.
Symptoms of fatigue
Even though the present thesis identified several predictors of fatigue,
and showed that fatigue is a risk marker for adverse events in CHF, it is still a
poorly understood symptom, especially from a physiological point of view.
Similar to vital exhaustion, studies are needed to test the associations between
the subjective experience of fatigue and relevant parameters in CHF, like
enhanced ergo reflex response, and increased levels of pro-inflammatory
markers (38,39,54).
Latent class analysis revealed multiple trajectories of exertion fatigue
and general fatigue. Although associations were found between mortality and
the more extreme (stable) groups, no associations were found with trajectories
that displayed changes in fatigue over time. The trajectories that displayed
change were generally small groups of patients, and usually lacked power to
confirm an association with mortality. In chapter 4, the increasing vital
exhaustion trajectory did in fact predict adverse events in CHF, but the sample
of this study was twice as big as compared to the trajectory analysis on
exertion and general fatigue. Hence, larger samples are required to determine
whether trajectories of exertion and general fatigue, that display changes over
time, are clinically significant.
Future interventions should focus on decreasing fatigue in CHF as
recommended by the European Society of Cardiology (56). Symptom relief is
also one of the most important targets of care and treatment for the patients
themselves (57,58). Venues for interventions could be exercise training,
support groups, or cognitive behavioural therapy (20,55,59,60).
In order to provide optimal treatment, some patients may need more
intensive follow-up as compared to others. The present thesis suggests that
especially those patients with severe exertion fatigue (chapter 8) or increasing
exertion fatigue over time (chapter 7) are at increased risk for adverse events.
In addition to cardiologists and general practitioners, other health care
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professionals such as nurse practitioners and psychologists might potentially
contribute to better care and management of CHF patients.
Limitations and strengths of the thesis
The present thesis had some limitations. First, there may have been
bias in the selection of patients. The cardiologist or heart failure nurses asked
patients to participate in the study, and this interaction pattern may have
influenced selection. For example, patients that go along well with their doctor
may more easily have agreed to participate.
Second, all CHF data were collected in the same hospital. This could
make generalizations of the results difficult. Multi-centre studies are needed to
confirm our findings in the CHF population at large.
Third, psychological variables were assessed by means of
questionnaires. It has been shown that measurement by questionnaires is not
very accurate (61). Response errors can be due to poor memory, poor
comprehension, personal norms and values, and social desirability (61,62). In
a recent study, a response set without questions was administered to a sample
of students together with two personality questionnaires. Surprisingly, it was
found that positive answers were associated with low neuroticism, high
extraversion, and high well-being (63). The results of this study potentially
question the validity of some of the associations found in this thesis. For
example, the associations between Type D personality and symptoms of fatigue
and depression reported in chapter 2. Perhaps, these associations are partly
the result of a general tendency towards positive or negative response
categories. This notion is also important when psychological factors are used as
predictors of hard medical outcomes. How valid are our measures on a
conceptual level? Do we really measure fatigue, depression, or personality as
distinct concepts? Perhaps it is the shared variance between psychological
measures that explains the association with adverse outcomes.
On the other hand, this thesis also had a number of strengths. First,
the repeated assessment of vital exhaustion and fatigue over time and the
prospective design that was used in most chapters provided the opportunity to
not only study between-subject variance, but also within-subject variance.
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Second, the use of advanced statistical techniques gave us more
detailed information. Chapter 4 and 8 applied latent class mixture modeling
which allows for the identification of distinct groups of patients following a
similar behavioral pattern over time. This method provided us with some
interesting subgroups of CHF patients with differential risks for health
outcomes. A related method was used in Chapter 2, latent class cluster
analysis, which was used to identify profiles of vital exhaustion. Latent class
cluster analysis is preferred over traditional cluster analysis because the cluster
criterion is less arbitrary, no decision on the scaling of observed variables has
to be made, and there are more formal criteria on which to base decisions on
the number of clusters.
Concluding remarks
Fatigue and vital exhaustion are important but neglected issues in CHF.
Severe and persistent vital exhaustion, exertion fatigue, and general fatigue
were present in a significant proportion of patients with CHF. It was shown that
psychological factors (e.g. Type D personality, depressive symptoms)
influenced the perception of symptoms of general fatigue and vital exhaustion,
and should be taken into account when health care professionals evaluate the
patient's symptom presentation. Exertion fatigue was less dependent on
psychological factors. Future studies should examine the associations between
fatigue, vital exhaustion, and relevant physiological parameters to determine
the extent to which the subjective experience of these symptoms reflect
disease related and/or psychological processes. This information is vital to help
guide future interventions aimed to reduce symptoms in CHF.
Vital exhaustion and exertion fatigue turned out to be powerful
predictors of adverse outcomes in CHF. Inconsistent results were found for
general fatigue in this regard, and can be used to identify high-risk patients.
These patients should be provided with more intense follow-up to improve their
symptom levels, and potentially prolong their survival. Future studies are
needed to develop effective treatment modalities to achieve this.
Overall, it can be concluded that there is an urgent need to understand
symptoms in CHF. The findings from the present thesis clearly demonstrate the
importance of fatigue and vital exhaustion in this context.
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Nederlandse samenvatting (Dutch summary)
De prevalentie van chronisch hartfalen neemt vandaag de dag
epidemische vormen aan. De belangrijkste oorzaken hiervan zijn het
toenemend aantal ouderen, en verbeterde behandelingsmogelijkheden na een
hartinfarct. Kenmerkend voor deze patiantengroep is een slechte tot matige
pompfunctie van het hart. In veel gevallen leidt dit tot klachten van
kortademigheid en vermoeidheid. Onderzoek heeft uitgewezen dat
hartfalenpatienten vermoeidheid ervaren als het meest belastende symptoom
van hun ziekte. Wetenschappelijk onderzoek naar de rol van vermoeidheid bij
hartfalen vindt echter op zeer beperkte schaal plaats.
In het eerste deel van dit proefschrift is de rol van vitale uitputting bij
hartfalen onderzocht. Vital uitputting kan gedefinieerd worden als een toestand
gekenmerkt door vermoeidheid, stemmings-, slaap-, en
concentratieproblemen. Voorgaand onderzoek heeft aangetoond dat vitale
uitputting een belangrijke precursor is van een hartinfarct. In de context van
hartfalen is de rol van vital uitputting tot op heden onderbelicht gebleven.
In hoofdstuk 2 is de aard van vitale uitputting bij hartfalen nagegaan.
Met behulp van een principale componenten analyse kon de onderliggende
structuur van vital uitputting worden onderschreven, namelijk een toestand
gekenmerkt door vermoeidheid, stemmings-, slaap-, en
concentratieproblemen. Deze factoren zijn vervolgens gebruikt om te komen
tot een profilering van vitale uitputting bij hartfalen. Aan de hand van een
latente cluster analyse konden drie verschillende profielen van vital uitputting
geidentificeerd worden: een subgroep van patianten die laag scoorden op alle
factoren van vitale uitputting, een subgroep van patianten die hoog scoorden
op alle factoren van vitale uitputting, en een subgroep van patienten die hoog
scoorden op vermoeidheid en concentratieproblemen, maar laag scoorden op
stemmings- en slaapproblemen. Vervolgens bleek dat de subgroepen met
verhoogde scores op vital uitputting een verminderde gezondheidstoestand
hadden, en dat deze subgroepen een verhoogde kans hadden op heropname in
het ziekenhuis vanwege hartfalen. De resultaten van hoofdstuk 2 laten zien dat
het van belang is om te focussen op clustering van verschillende
(psychologische) factoren. Het in ogenschouw nemen van symptoomprofielen
zou namelijk kunnen leiden tot meer gerichte en meer efficiente interventies.
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In hoofdstuk 3 is ingegaan op de vraag in hoeverre klachten van vital
uitputting bepaald worden door de mate van ischemisch hartlijden ten opzichte
van persoonlijkheidskenmerken. Uit de resultaten bleek dat de mate van
ischemisch hartlijden geen invloed had op klachten van vital uitputting.
Daarentegen bleek dat patienten met een Type D persoonlijkheid, gekenmerkt
door een combinatie van negatieve affectiviteit en sociale inhibitie, een grotere
kans hadden op klachten van vitale uitputting ten opzichte van patianten
zonder deze persoonlijkheidskenmerken. Bij de evaluatie van
gezondheidsklachten zou daarom ook rekening gehouden moeten worden met
de persoonlijkheid van de patunt.
In hoofdstuk 4 is het verloop van vitale uitputting over een periode van
12 maanden bestudeerd. Aan de hand van een latente klassen mixture
modellering werden een viertal verschillende trajecten gevonden: een traject
met stabiele, lage scores op vitale uitputting, een traject met toenemende
scores op vitale uitputting, een traject met een afnemende scores op vitale
uitputting, en een traject met stabiele, hoge scores op vitale uitputting. Bijna
de helft van alle hartfalenpatienten bleek te zitten in de groep met stabiele,
hoge scores, ondanks optimale medische behandeling. Verder bleek dat
patienten in deze groep een significant hogere kans hadden op een slechte
prognose.
In het tweede deel van dit proefschrift is de rol van
inspanningsvermoeidheid en algemene vermoeidheid bij hartfalen onderzocht.
Inspanningsvermoeidheid kan gezien worden als vermoeidheid die het directe
gevolg is van activiteiten in het dagelijks leven, terwijl algemene vermoeidheid
niet direct een relatie met inspanning hoeft te hebben. Ook voor deze vormen
van vermoeidheid geldt dat er relatief weinig onderzoek naar is gedaan binnen
de context van hartfalen.
In hoofdstuk 5 zijn voorspellers van inspanningsvermoeidheid en
algemene vermoeidheid onderzocht. Uit de resultaten bleek dat
inspanningsvermoeidheid het beste voorspeld werd door inspanningscapaciteit,
kortademigheidsklachten, hypertensie, en depressieve klachten. Daarentegen
werd algemene vermoeidheid het beste voorspeld door
kortademigheidsklachten, depressieve klachten, Type D persoonlijkheid, en
slaapproblemen.
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In hoofdstuk 6 is een vergelijking gemaakt tussen algemene
vermoeidheidsklachten bij hartfalenpatienten ten opzichte van
herseninfarctpatiianten. Bij herseninfarctpatianten lijkt vermoeidheid nog een
meer genegeerde klacht te zijn dan bij hartfalen. Uit de resultaten van
hoofdstuk 6 bleek echter dat het niveau van vermoeidheidsklachten bij
hartfalers en herseninfarctpatienten vergelijkbaar is.
In hoofdstuk 7 is onderzocht in hoeverre verandering van vermoeidheid
over tijd voorspellend is voor de prognose op langere termijn. Toename in
inspanningsvermoeidheid tussen de baseline en 12 maanden follow-up bleek
een significante voorspeller te zijn van een slechte prognose, ook na controle
voor standaard risicofactoren zoals roken en diabetes.
In hoofdstuk 8 is het verloop van inspanningsvermoeidheid en
algemene vermoeidheid bestudeerd. Aan de hand van een latente klassen
mixture modellering werden 6 verschillende trajecten gevonden voor
inspanningsvermoeidheid, en 4 verschillende trajecten voor algemene
vermoeidheid. Uit vervolganalyses bleek dat patienten met stabiele en hoge
scores op inspanningsvermoeidheid en algemene vermoeidheid een hogere
kans hadden op vroegtijdig overlijden in vergelijking met patienten met
gematigde vermoeidheidsscores. Hartfalenpatienten met stabiele en lage
scores op inspanningsvermoeidheid hadden juist een verminderde kans op
vroegtijdig overlijden.
Ten slotte is in hoofdstuk 9 de relatie tussen somatisch-affectieve
symptomen van depressie, vermoeidheid, en prognose nagegaan. Een recente
studie heeft aangetoond dat de relatie tussen depressie en prognose bij
hartfalen verklaard wordt door de somatisch-affectieve component van
depressie. In dit hoofdstuk is onderzocht of vermoeidheid vervolgens het effect
van somatisch-affectieve symptomen van depressie op prognose zou kunnen
verklaren. Uit de resultaten bleek echter dat somatisch-affectieve symptomen
van depressie voorspellend waren voor een slechte prognose bij hartfalen ook
na correctie voor vermoeidheidsklachten.
De resultaten van dit proefschrift laten zien dat persisterende klachten
van vitale uitputting, inspanningsvermoeidheid, en algemene vermoeidheid
frequent aanwezig zijn bij hartfalenpatienten. Daarnaast is gebleken dat
psychologische factoren zoals depressie en persoonlijkheid invloed hebben op
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de symptoomperceptie van patienten. Clinici zouden hier rekening mee moeten
houden bij de evaluatie van klachten die hartfalenpatienten naar voren
brengen. Vitale uitputting en inspanningsvermoeidheid bleken ook krachtige
voorspellers te zijn van een slechte prognose bij hartfalen. Patienten met
vermoeidheidsklachten zouden daarom meer intensief opgevolgd moeten
worden. Vermindering van vermoeidheidsklachten zou kunnen leiden tot een
betere kwaliteit van leven, en mogelijk ook tot een verbeterde prognose.
Toekomstig onderzoek zal moeten leiden tot effectieve interventies gericht op
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